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RÉSUMÉ 
Étude de l’interaction NHE6/RACK1 : développement d’un inhibiteur peptidique 
visant à prévenir la chimiorésistance induite par l’hypoxie 
 
Par 
Pierre-Paul Pelletier 
Programme d’immunologie, Département de pédiatrie 
 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maitre ès sciences (M.Sc.) en immunologie, Faculté de médecine et des 
sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Les cellules tumorales exposées à l’hypoxie sont connues pour développer une résistance 
accrue aux traitements de chimiothérapie. Ce phénomène est attribué à plusieurs facteurs. 
Tout d’abord, peu de drogue en circulation atteignent les régions hypoxiques tumorales mal 
perfusées. Le métabolisme des cellules tumorales en hypoxie est altéré de façon à créer un 
milieu extracellulaire sur-acidifié qui nuit à la perméabilité membranaire de certaines 
drogues. Des mécanismes cellulaires tels que l’arrêt du cycle cellulaire, l’inhibition de 
l’apoptose et l’expression de pompes à efflux s’additionnent aux facteurs tissulaires de 
résistance. En 1996, il fut observé que des cellules MCF7 résistantes à la doxorubicine 
possédaient des compartiments intra-vésiculaires plus acides que leurs homologues sensibles 
à la doxorubicine. Selon le modèle de protonation, séquestration et sécrétion (PSS), proposé 
pour expliquer cette découverte, les drogues qui agissent à titre de bases faibles peuvent être 
séquestrées dans des compartiments acides suite à leur protonation et être sécrétées par la 
suite. Nos résultats ont démontré que la culture en hypoxie mène à une acidification des 
compartiments intra-vésiculaires accompagnée d’une augmentation de la résistance aux 
traitements d’agents chimiothérapeutiques de type anthracycline dans des lignées cellulaires 
de divers types de cancer. L’imagerie confocale nous a permis d’observer une localisation 
extranucléaire de la doxorubicine qui co-localise de façon partielle avec un marqueur 
endosomal, la transferrine. Cette étude cherchait d’abord à évaluer l’implication de 
l’échangeur endosomal NHE6 dans l’acidification intravésiculaire produite par l’hypoxie. De 
plus, le projet visait à concevoir une stratégie pour contrer cette acidification et améliorer la 
réponse aux anthracyclines. Les résultats obtenus démontrent que l’hypoxie affecte la 
localisation de NHE6 ce qui contribue à l’acidification intravésiculaire des endosomes. Le 
changement de localisation de NHE6 s’effectue suite à une interaction directe et transitoire 
avec la protéine d’échafaudage RACK1. L’expression d’un peptide de compétition dérivé 
d’une séquence de 62 aa de NHE6, nous permet de contrer la délocalisation de l’échangeur, 
de réduire l’ampleur de l’acidification intravésiculaire et d’atténuer la résistance aux 
anthracyclines causés par l’hypoxie. Une analyse in-silico reposant sur la conservation de 
résidus fonctionnels, les propriétés biochimiques des interfaces d’interaction protéine-
protéine transitoires, ainsi qu’un protocole de raffinement d’arrimage moléculaire, a permis 
de mettre en lumière une courte portion de la région d’interaction susceptible de permettre 
l’ancrage de NHE6 à travers une cavité à la surface de RACK1. 
  
Mots clés : Chimiorésistance, hypoxie, pH intracellulaire, NHE6, RACK1, tumeur 
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SUMMARY 
Study of the NHE6/RACK1 interaction : design of a peptidic inhibitor for the 
prevention of hypoxia-induced chemoresistance 
 
By 
Pierre-Paul Pelletier 
Immunology Program 
 
Thesis presented to the Faculty of Medicine and Health Sciences for the obtention of a 
Master’s Degree in Sciences (M.Sc.) in Immunology, Faculty of Medicine and Health 
Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Tumor cells exposed to hypoxia are known to develop resistance to chemotherapy. Several 
components have been shown to contribute to such resistance. Previous studies indicate that 
only a small amount of the drug in circulation is able to penetrate poorly perfused hypoxic 
areas of tumors. Hypoxia alters the metabolism of tumor cells and leads to acidosis of the 
extracellular fluid thus altering the ability of various drugs to cross lipid bilayers. 
Compounded with resistance factors observed in living tissues are cellular mechanisms such 
as cell cycle arrest, inhibition of apoptosis and the expression of drug efflux pumps. In 1996, 
it was observed that doxorubicin resistant MCF7 cells have more acidic intra-vesicular 
compartments than their doxorubicin sensitive counterparts. According to the protonation, 
sequestration and secretion (PSS) model, which was proposed as an explanation for the 
aforementioned discovery, drugs that act as weak bases can be sequestered in acidic 
compartments following protonation and eventually be secreted. Our results obtained in 
several cancer cell lines have shown that the incubation of the cells under hypoxic conditions 
leads to an acidification of intra-vesicular compartments and an increased resistance to 
anthracycline. Using confocal imaging we were able to visualize extranuclear doxorubicin 
spots that partially co-localized with the transferrin endosomal marker. The initial goal of 
this study was to evaluate the implication of the endosomal Na+/H+ exchanger, NHE6, in 
intra-vesicular acidification induced by hypoxia. Additionally, the project aimed to elaborate 
a strategy to counter this acidification and to improve the response to anthracycline drugs. 
Our results demonstrate that hypoxia affects NHE6 localization which contributes to intra-
vesicular acidification. NHE6 change of localization takes place through a direct transient 
interaction with the scaffold protein RACK1. Expression of a competition peptide derived 
from a 62 aa sequence of NHE6, was used to block NHE6 delocalization, to reduce the 
magnitude of intra-vesicular acidification and to attenuate the effect of anthracycline 
resistance caused by hypoxia. An in-silico analysis based on the conservation scores of 
functional residues, biochemical properties of transient protein-protein interfaces, as well as 
a molecular docking refinement protocol, has allowed us to detect a short segment of the 
region of interaction that may be necessary for NHE6 anchorage on a surface cavity of 
RACK1. 
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1. INTRODUCTION 
1.1 Clinical Consequences of the Chemoresistance Problematic Faced in Oncology 
Several projects from which rose precursors to modern chemotherapy took place during 
World War II, including the nitrogen mustards, alkylating agents that were the first 
chemotherapeutic agents used to treat cancer (DeVita and Chu, 2008). The early compounds 
used for chemotherapy were typically biological compounds isolated from living organisms 
that would later be chemically modified to give rise to chemotherapeutic classes with a large 
number of synthetic analogs.  Examples of such include: analogs of folic acid, the first 
antifolates developed and tested during the 1940’s (DeVita and Chu, 2008), 5-flurouracyl, a 
modified uracil nucleobase (DeVita and Chu, 2008), both vincristine and vinblastine, plant 
alkaloids isolated from Catharanthus roseus (Moudi et al, 2013) and both daunorubicin and 
doxorubicin, anthracyclines that were isolated from the gram-positive soil bacteria 
Streptomyces peucetius (Di Marco et al, 1981). These projects would eventually lead to the 
development of compounds that became regularly used in the 1960’s for cancer treatment in 
the clinic alongside surgery, hormone therapy and radiotherapy (DeVita and Rosenberg, 
2012). The latest forms of cancer treatment to have made their appearance in clinical practice 
are immunotherapy and targeted therapy in the late 1990’s (DeVita and Rosenberg, 2012). 
 
Following early success in the late 1990’s and early 2000’s of the Bcr-Abl tyrosine kinase 
inhibitor Imatinib (Gleevec) used to treat chronic myelogenous leukemia (CML), targeted 
therapies used in personalized medicine have been widely acclaimed as the future of cancer 
therapy because of high success rates and few side effects (DeVita and Chu, 2008). However 
targeted therapies present their own set of challenges: they rely heavily on biomarkers for 
diagnostic purposes, each therapy can only be used for a limited subset of patients presenting 
the specific molecular target and they have limited potential for treatment of cancers with 
intratumor heterogeneity (Curigliano and Criscitiello, 2014).  Steady progress has been made 
in the development and usage of targeted therapies over the last two decades, however 
research to identify practical biomarkers and to fully understand the consequences of tumor 
heterogeneity is still in its early stages. Therefore, it remains to be seen to which extent 
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targeted therapy can rise to the future challenges of oncology (Fisher et al, 2013). First-line 
treatments for solid tumors such as surgery and radiotherapy have limited benefits when used 
alone for tumors in advanced stages with poorly defined borders and in which metastases 
have occurred (Kirkwood et al, 2013). Likewise, these techniques can rarely be used 
effectively to treat cancers such as leukemia and lymphoma that do not depend on the 
formation of solid tumors (Greaves, 2016). For all of these reasons, despite high toxicity, 
chemotherapy remains one of the most commonly used forms of treatment in oncology. For 
many types of cancers primary chemotherapy offers the best option to improve progression 
free survival although it is not used for curative purposes (Table 1) (DeVita and Chu, 2008). 
Combination chemotherapy is used effectively for the treatment of several types of leukemia 
and lymphoma, it is also used as neoadjuvant therapy to reduce tumor size before surgical 
resection and as adjuvant therapy to reduce the likelihood of local or metastatic recurrence 
post-surgery (DeVita and Chu, 2008). Adjuvant chemotherapy used in a post-surgical setting 
generally yields greater benefit than equivalent primary therapy used in cases of unresectable 
tumors (Kirkwood et al, 2013). Cancer staging and use of prognosis factors is becoming 
increasingly precise and intricate to help guide the choice of therapy regimen that yields the 
best risk/benefit ratio for each individual patient.  
 
Table 1: Types of cancer in which clinical practice indicates primary chemotherapy 
for advanced cases and in which adjuvant therapy is indicated following surgery. 
Type of cancer Primary 
chemotherapy 
Adjuvant 
chemotherapy 
Anaplastic astrocytoma  √ 
Bladder √  
Breast √ √ 
Cervical √ √ 
Colorectal √ √ 
Esophageal √  
Gastric √ √ 
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Head and Neck √ √ 
Melanoma  √ 
Nasopharyngeal √  
Non-small cell lung √ √ 
Osteogenic sarcoma  √ 
Ovarian √ √ 
Pancreatic √  
Prostate √  
(Adapted with permission from DeVita and Chu, 2008, American Association for Cancer Research License n°  
4107690780581) 
 
Cancer treatments that fall under the umbrella term of chemotherapy are drugs that inhibit 
cancer growth by impairing mitosis in fast dividing cells. They are thus cytotoxic compounds 
that differ from targeted therapies, hormone therapy and immune therapy because of their 
lack of specificity and of their significant toxicity. Although cytotoxic drugs are the preferred 
treatment in many cases as described above and have shown better effects than alternatives 
for prolonging remission, it remains that response rates are low and that development of 
resistance as manifested by relapse is nearly universal. Treatment regimens that include 
anthracycline such as doxorubicin have represented one of the most viable options for 
decades for the treatment of aggressive tumors. As for all the classes of chemotherapeutic 
agents, resistance regularly arises and deeply compromises the response to such an adjuvant 
therapy regimen.  
 
Chemoresistance has been observed to occur across all types of cancers irrespectively of the 
tissue of origin. It has been categorized under two large categories based upon the response 
to the initial therapy; cancer that does not respond to initial therapy is deemed intrinsic 
resistance whereas cancer that returns after an initially successful therapy is called acquired 
resistance (Lippert et al, 2011). Examples of cancers that display intrinsic resistance, which 
is also called primary resistance, include acute lymphoblastic lymphoma (ALL) where 
approximately 20% of adult patients exhibit resistance when they first undergo treatment 
(Thomas et al, 1999). Patients with adenocarcinoma that undergo the prescribed treatment of 
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chemotherapy with surgery are 50 to 70% likely to relapse within a year and in most of those 
cases a phenotype of chemoresistance is acquired (Castells et al., 2012). Breast cancer is by 
far the most common form of cancer in women worldwide, affecting approximately 1 of 8 
women at one point during their lifetime and accounting for about 14% of new cancer cases 
(Ferlay et al, 2015; Verwey et al, 2016). Aside from being highly prevalent, breast cancer is 
a type of cancer that is known to have frequent recurrences in the form of treatment resistant 
tumors during the years that follow surgery with neoadjuvant or adjuvant therapy (Arnason 
and Harkness, 2015). It has been estimated that 40% of breast cancer patients undergoing 
conventional treatment will eventually relapse and in the majority of those cases the returning 
tumors will be from metastasis; this is at least partially due to development of resistance to 
either chemotherapy or radiation therapy (Smalley, 2013). Although conventional therapy is 
usually effective for the treatment of a primary tumor it is much less so for treatment of 
resistant secondary tumors at the sites of metastasis (Verwey et al, 2016). Treatment outcome 
thus depends largely on tumor aggressiveness and metastatic potential. Breast cancer 
classification based on the presence or absence of the estrogen, progesterone and human 
epidermal growth factor-2 (HER2) receptors gives insight into the treatment approach to be 
used and into the aggressiveness of the tumor (Verwey et al, 2016). Triple negative breast 
cancer (TNBC) tumors are the most challenging to treat because they are insensitive to 
hormone therapy, are the most aggressive and are the most likely to recur in the form of 
resistant tumors from metastatic sites (O’Reilly et al, 2015). Effective treatments for TNBCs 
are currently lacking and urgently needed; predictive factors to guide treatment for this type 
of cancer also need to be developed and refined (Rakha & Chan, 2011).  
 
Two alternate models have been postulated to explain the origin of chemotherapy resistant 
cells (Zharedine and Borden, 2013). In the first model, a small number of quiescent cancer 
stem cells (CSC) are thought to have properties that enable them to initiate tumor formation 
and to provoke resistance (Nguyen et al, 2012). According to the second model, called 
environment mediated drug resistance (EMDR), the tumor microenvironment plays a large 
role in modulating the entrance of tumor cells into a dormant state (Meads et al, 2009). This 
dormant state allows them to survive long enough under selective pressure to undergo genetic 
alterations that confer drug resistance even when exiting the dormant state (Meads et al, 
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2009). Proponents for either model have put together strong supporting arguments in both 
cases and although most investigators in the field of chemoresistance prefer to explain their 
findings according to one model, there is no reason why they could not be complementary. 
For the remainder of this dissertation, we have chosen to rationalize our findings under the 
lens of the EMDR model although we recognize that resistance arising as described in the 
CSC model may also have occurred. 
 
Extrinsic microenvironment factors leading to chemoresistance that fall under the scope of 
the EMDR model can be either physical factors, soluble factors or can be linked to cell-
adhesion mediators. Known physical factors include hypoxia and acidosis whereas known 
soluble factors include cytokines, chemokines and growth factors; cell-adhesion mediators 
include changes to integrins and other cell-adhesion molecules that often take place during 
epithelial-mesenchymal transition (EMT) (Meads et al, 2009).  
 
Because the development of human cancer usually involves genomic instability that leads to 
an accumulation of point mutations and epigenetic modifications, a majority of tumors are 
comprised of highly heterogeneous populations of cells (Caulin and Maley, 2011. Epithelial 
breast carcinomas are a particularly striking example in which it has been reported that high 
intra-tumor diversity was found in 97% of tumors examined (Wild et al, 2000). Mutations 
acquired in cancer sub-populations can provide survival advantages for certain contexts, such 
as under therapeutic pressure. In such contexts, heterogeneous tumors obey the Darwinian 
law of evolution by natural selection; tumor clones that have undergone favourable 
adaptations are able survive therapy whereas all or most other clones are eliminated (Greaves, 
2007). Although therapy might initially appear to have been successful because of tumor 
shrinkage, a niche of highly resistant cells in a dormant state (Meads et al, 2009) may remain 
and can eventually repopulate the tumor to cause relapse. 
 
The problematic behind chemoresistance acquired under therapeutic selective pressure is 
compounded by the fact that favourable adaptations to one therapy will also negatively affect 
the efficacy of ensuing therapies. This phenomenon is associated with poor treatment 
outcome and prognosis, and it is recognized as multidrug resistance (MDR) (Ullah, 2008). 
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Specific mechanisms of MDR and examples will be described in a later section; for the scope 
of this thesis, we will discuss MDR in the context of chemotherapy resistance although it 
also occurs in response to other distinct compounds such as for antibiotics. 
 
Cancer resistance to therapy is not singly limited to chemotherapy; resistance to targeted 
therapies and to immunotherapy have been observed and described. Unlike for 
chemotherapy, mechanisms of resistance to these therapies tend to involve specific molecular 
targets and pathways and do not typically give rise to MDR. The targeting of oncogenes 
around which cancer cells develop oncogene addiction has become a popular strategy for the 
design of therapies (Weinstein and Joe, 2008). That is because in many cases cancer cells 
become over reliant on these oncogenes and cannot survive if they become inactivated. In 
the case of tyrosine kinase oncogenes, mutations to gatekeeper residues of the kinase domain 
has been shown to lead to constitutive activation of the enzyme which renders targeted 
therapies ineffective; such examples have notably been demonstrated for BCR-ABL fusion 
protein, for epidermal growth factor receptor (EGFR), and for platelet-derived growth factor 
receptor (PDGFR) isoforms α and β (Azam et al, 2008). In other cases, targeted pathways 
that were initially believed to be essential for tumor survival can effectively be substituted 
for by a parallel pathway. One such example is the emergence of the insulin-like growth 
factor 1 receptor (IGF1R) pathway following treatment with phosphatidylinositol 3-kinase 
(PI3K) inhibitors that gives rise to PI3K inhibitor resistant cell lines (Isoyama et al, 2012). 
 
Novel cancer therapy regimens are now being engineered to attempt to overcome the ever-
present problematic of chemoresistance. Improved understanding of molecular events 
leading to resistance has been imperative for the recent advances in this field. As proposed 
by Hall et al (2009), an effective strategy to overcome MDR could rely on identifying the 
new “Achilles’ heel” of resistant tumors; a concept the authors refer to as collateral sensitivity 
(CS). According to this principle, adaptations that have made tumor cells resistant to one type 
of therapy may also hypersensitize them to other types of therapies. CS has certainly been 
observed and exploited for targeted therapies where PI3K inhibitor resistant cell lines have 
been treated in conjugation with selective IGF1R inhibitors for much more convincing 
outcomes (Isoyama et al, 2012). The concept of CS builds on the mathematical model of 
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tumor resistance to chemotherapy proposed by Coldman and Goldie (1983), in which being 
able to pinpoint alternating non-cross-resistant chemotherapy would be the optimal route for 
treatment. Therapies with specific cellular targets can now be used along with chemotherapy 
to exploit CS, a strategy that appears to be the most promising avenue for the development 
of future combination therapies.  
 
1.1.1 Chemoresistance in Solid Tumors 
Up to now, most of the research on resistance to chemotherapy has been focused on 
molecular adaptations of cancer cells leading up to cellular mechanisms of chemoresistance 
(Yu & Tannock, 2012). Many of the proposed therapeutic strategies that have emerged from 
these studies have however neglected to consider the effects that tumor microenvironment 
characteristics can have on hindering therapeutic efficacy (Wojtkowiak et at, 2012). Indeed, 
physiological factors can exacerbate resistance to chemotherapy by limiting the amount of 
drug in the circulation that reaches and penetrates tumor cells (Yu & Tannock, 2012). 
Physical microenvironment factors also act as stressors that, as per the EMDR model, select 
for molecular adaptations that favour survival under these harsh physical conditions and that 
coincidentally also confer increased resistance to chemotherapy (Doktorova et al, 2015). 
Although increased interstitial fluid pressure (IFP), nutrient deprivation, hypoxia and 
acidosis, might at first glance appear to act separately on resistance to chemotherapy, there 
is increasing evidence of the interplay that exists between these common physical factors of 
the tumor microenvironment. This section summarizes the current state of research regarding 
how extrinsic tumor microenvironment factors affect chemoresistance and highlights known 
interactions between these factors. 
 
1.1.1.1 Increased Interstitial Fluid Pressure and Tumor Hypoxia 
A fundamental difference between solid tumors and normal tissues is the increased rate of 
cancer cell proliferation. Because the rate of proliferation exceeds the capacity of existing 
and newly formed vasculature to provide a proper supply of nutrients and oxygen, it is a 
common feature of solid tumors to contain areas impoverished in nutrients and oxygen (Chan 
& Giaccia, 2007). In fact, O2 has a diffusion limit of about 100-200 μm around tumor blood 
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capillaries which means that hypoxic regions usually start forming in tumors that reach 1-2 
mm in diameter (Egeblad et al, 2010). It has been estimated that nearly 40% of all breast 
tumors contain important hypoxic areas associated with increased resistance to chemotherapy 
and radiotherapy (Ward et al, 2013). Oxygen concentration in these areas can drop below 
0.3% whereas the oxygen concentration of normal breast tissues is typically around 9% 
(Chun et al, 2006). A correlation between hypoxia, chemoresistance and resistance to 
radiotherapy has also been observed in several other types of solid tumors (Jia & Nan, 2011). 
Resistance to radiotherapy is due, at least in part, directly to low oxygen concentrations; the 
mechanism of action of radiotherapy requires the formation of cytotoxic free radicals in a 
reaction with oxygen to damage the integrity of DNA and halter proliferation (Pajonk et al, 
2010). Along with other factors, this phenomenon can increase resistance to radiation doses 
by 2-3-fold. Hypoxia is also recognized to enhance the invasive potential of tumors. In this 
regard, hypoxia was shown to contribute to local invasion and to increase incurrence of 
metastasis at distant sites (Jia & Nan, 2011). Studies examining transcription of miR-210, 
GLUT1 and carbonic anhydrase IX (CAIX) as well as protein expression of GLUT1 and 
CAIX in TNBC associated with a poor prognosis reveal that the hypoxic response is likely 
stronger than for other types of breast cancers (Ward et al, 2013). It is thus no surprise that 
tumor hypoxia has become a strong indicator of poor clinical prognoses for many types of 
cancers (Doktorova et al, 2015). 
 
As a tumor expands within its host tissue, it exerts pressure onto the surrounding stroma that 
resists the increase in volume (Stylianopoulos, 2016). This phenomenon results in a stiffening 
of the tumor due to densification of the extra-cellular matrix (mostly hyaluronan and 
collagen) and stroma (Yu & Tannock, 2012). The mechanical stress that is generated by 
tumor expansion also compresses intratumoral and surrounding blood and lymphatic vessels 
(Stylianopoulos, 2016). As perfusion from blood vessels and lymphatic vessel fluid drainage 
are hindered, IFP is invariably elevated. This increased IFP poses a major barrier to 
chemotherapy by reducing the ability of drugs to penetrate tumor tissue (Yu & Tannock, 
2012). Tumor capillaries can eventually collapse if their internal pressure is exceeded by IFP; 
tumor vasculature collapse further limits delivery of chemotherapy, of oxygen and of 
nutrients. As a whole, solid tumor vasculature has been shown to be more disorganized than 
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for normal tissues and the distance between functional capillaries of tumors is wider than for 
normal tissues. Since the tumor vasculature is constantly changing, the tumor 
microenvironment becomes a continuously fluctuating landscape of oxygen and nutrient 
gradients. Therapeutic strategies targeting the extracellular matrix (ECM) and stromal cells 
are being explored to help normalize the IFP and to improve chemotherapy delivery as well 
as restore normal vasculature architecture in tumors (Yu & Tannock, 2012). These strategies 
include disruption of Hedgehog signaling to deplete tumor-associated stromal fibroblasts 
(TAF) (Olive et al, 2009) or treatment with PEGPH20, an enzyme that degrades hyaluronan 
(Yu & Tannock, 2012).  
 
The most studied mediators of the hypoxic response have undoubtedly been the Hypoxia 
inducible factor (HIF) transcription factors; dimeric complexes formed of a HIF1α, HIF2α 
or HIF3α labile subunit and a stable HIF1β (also called ARNT) which as a complex can bind 
hypoxia responsive elements (HRE) and act as important transcriptional regulators (Keith et 
al, 2012). HIF alpha subunits are labile under normal oxygen tension where they are modified 
by HIF-specific prolyl-hydroxylases (PHDs) and targeted for proteasomal degradation via 
E3ubiquitin ligase von Hippel-Lindau tumor suppressor protein (pVHL). Levels of HIF1α 
and HIF2α expression and ensuing activity of the mature dimeric complex are primarily 
controlled through this post-translational mechanism where PHDs require oxygen as a 
substrate to allow specific recognition of HIFα subunits by pVHL. Low oxygen tension thus 
leads to stabilization of HIFα subunit and modulation of HRE containing genes. Up to now, 
more than 100 genes controlled by HIF-1 have been identified and new targets are constantly 
being added to the list (Yu et al, 2017); it is thus understandable that most of the research on 
the hypoxic response has been focused on HIF1α which also happens to be ubiquitously 
expressed across human tissues unlike its HIFα counterparts. The remainder of the discussion 
on HIF transcription factors will thus focus on HIF1α; the dimeric protein containing HIF1α 
will be henceforth referred to as HIF-1.  
 
Genes modulated by HIF-1 fall under a broad range of normal and abnormal cellular 
processes such as proliferation, cell cycle control, glycolysis, angiogenesis, erythropoiesis, 
invasion, migration and chemoresistance. Many of the genes identified thus far have been 
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associated with either cancer progression or maintenance (Ward et al, 2013). HIF-1α has 
been found to be commonly overexpressed across a wide range of malignant tumor types 
(Barar & Omidid, 2013). The list of genes modulated by HIF-1 is too extensive to be properly 
represented in this section but a few examples will be briefly presented to illustrate how HIF-
1 can be linked to cancer progression and maintenance.  
 
Several oncogenic driver mutations have been shown to increase HIF-1 irrespective of 
oxygen tension (Ward et al, 2013). Those include mutations leading to constitutive activation 
of Ras GTPases regulating MAPK/ERK pathway of growth and differentiation, of Src 
tyrosine kinase or of kinases from the PI3K/AKT/mTor pathway of cell cycle regulation. 
Likewise, activation of growth factor receptors such as IGF1R, EGF, HER2 and c-Met has 
also been shown to elevate levels of HIF-1 (Jia & Nan, 2011). A strong positive correlation 
with activity of these oncogenes as well as association with loss of function of phosphatase 
and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor 
suppressor genes indicate a role for HIF-1 as a regulator of cancer growth and progression 
(Barar & Omidi, 2013).  
 
Many of the cellular functions affected by the expression of HIF-1 favour cancer maintenance 
by contributing to a pro-survival phenotype. Among these, angiogenesis has repeatedly been 
shown to be associated with stabilization of HIF-1α (Bos et al, 2005). Cell cycle deregulation 
and activation of growth pathways alone would not allow a tumor to grow beyond a few 
millimetres in diameter due to poor vascularization and appearance of necrotic zones in the 
de-oxygenated core of the tumor (Yu & Tannock, 2012). By promoting angiogenesis under 
low, but not yet lethal oxygen tensions, HIF-1 allows renewal of blood vessels and continued 
growth of the tumor. These new vessels do little to re-establish proper drug perfusion in the 
tumor core as they are of poor integrity and form and abnormal architecture (Maugeri-Saccà 
et al, 2011).  
 
Glucose metabolism is another function that is significantly altered by HIF-1 expression. 
HIF-1 is indeed one of the key factors that lead to increased reliance on glycolysis by cancer 
cells, a metabolic shift widely known as the “Warburg effect”. It should be noted that 
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although we focus here on the role of HIF-1 in promoting glycolysis, the Warburg effect 
denotes a wide-ranging observation of glycolysis reliance by cancer cells that go beyond the 
effect of hypoxia and HIF-1. HIF-1 acts as a regulator of glycolysis by promoting the 
expression of pyruvate kinase M2 (PKM2) (Porporato et al, 2011), which acts as a rate-
limiting enzyme of this metabolic pathway as well as by promoting the expression of glucose 
transporters GLUT1 and GLUT4 (Marin-Hernandez et al, 2009). Since glycolysis does not 
strictly require oxygen for generation of adenosine triphosphate (ATP), this metabolic shift 
allows extended survival in regions impoverished in oxygen. The pro-survival effects of 
HIF1α however extend far beyond cancer cells exposed to hypoxia; in reality, HIF-1 also 
affects the metabolism of neighbouring cells under normoxia. That is because HIF-1 also 
controls the expression of lactate dehydrogenase (LDH) which is responsible for converting 
pyruvate, the end-product of glycolysis, into lactate (Semenza, 2009) as well as the ratio 
between plasma membrane monocarboxylate transporters 1 (MCT1) and 4 (MCT4) that 
respectively regulate its import and export (Ullah et al, 2006). The effect is a symbiotic 
relationship in which lactate is exported from tumor cells in hypoxia to be imported by tumor 
cells in normoxia and reutilized for oxidative phosphorylation; this mechanism allows for 
efficient glucose metabolism and optimized energy production.  
 
Although cancer progression and maintenance are often discussed separately due to the 
different cellular processes involved, these sometimes involve common signaling pathways. 
Such is the case for the PI3K/AKT/HIF1α that has been shown to be involved with EMT and 
chemoresistance for breast cancer (Semenza, 2003), hepatocellular carcinoma (HCC) (Jiao 
& Nan, 2012) and other types of carcinomas. The important role of HIF1α stabilization in 
cancer maintenance is illustrated through the concomitant expression of several markers of 
EMT and MDR strongly correlated with poor treatment outcome. In the first case, lysyl 
oxidase (LOX) (Rebucci & Michiels, 2013) , SNAIL, vimentin and N-cadherin come to mind 
(Imai et al, 2003), whereas BCRP, MDR-1 and c-MYC are some of the key markers 
identified to be associated with both hypoxia sustained expression and resistance to 
chemotherapy (Davies et al, 2014). 
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Specifically, LOX is a family of enzymes that catalyzes a reaction forming aldehydes from 
the lysine residues side chain amines of ECM proteins (Mayorca-Guiliani & Erler, 2013). 
Follows from this reaction spontaneous formation of cross-linkages between elastin and 
collagen fibers as part of the maturation process of ECM; through this mechanism, LOX has 
been shown to promote the formation of metastatic niches in several cancer types (Bennewith 
& Dedhar, 2011). LOX enzymes have additionally been shown to act in invasion and 
migration in early stages of the metastatic cascade (Erler et al, 2006). These effects of the 
LOX enzymes are due, at least in part, to LOX-induced stabilization of the SNAIL protein, 
which is a critical regulator of EMT (Sahlgren et al, 2008). SNAIL protein contributes to the 
loss of the epithelial phenotype in carcinomas undergoing EMT as it acts as a transcriptional 
repressor of the epithelial marker E-cadherin. Amongst the other important HIF-1-dependent 
genes that facilitate invasion and metastasis are the type IV collagen degrading 
metalloproteinases MMP2 and MMP9 that act by weakening the integrity of basement 
membranes (Gilkes & Wirtz, 2014). 
 
Many of the pro-survival characteristics observed in cells exposed to hypoxia have been 
associated to HIF1-induced genes that reprogram tumor cells to acquire stem cell-like 
characteristics (Crowder et al, 2014). Reprogramming of CSC genes through HIF proteins 
contributes to chemoresistance in several ways including by increasing genomic instability, 
by modifying the cell cycle, by favouring glycolysis (Crowder et al, 2014) or by controlling 
expression of multidrug efflux pumps (Jiao & Nan, 2012). Although HIF-1 is the most 
studied response to hypoxia and was most often reported as a mediator of chemoresistance 
and resistance to radiotherapy, it would be misleading to equate the pro-survival phenotype 
induced by hypoxia with HIF effects. A prominent example of a complementary mediator of 
chemoresistance prevalent in the hypoxic microenvironment would be the loss or inactivation 
of the P53 cell cycle regulator. The functional form of P53 indeed acts as a negative regulator 
of the hypoxic response by promoting proteasomal degradation of HIF proteins (Ward et al, 
2013). HIF-independent stress response pathways as well as dysregulated reactive oxygen 
species (ROS) and redox mechanisms are also becoming increasingly associated with the 
hypoxia response and MDR (Crowder et al, 2014). The relative contribution of the different 
elements of the hypoxic response towards chemoresitance remains largely elusive and will 
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undoubtedly continue to be clarified in the coming years. Current evidence suggests that 
oxidative stress is more severe in areas of intermittent hypoxia and that this type of hypoxia, 
as opposed to chronic or acute hypoxia, is mainly responsible for resistance in solid tumors 
(Kwee, 2014). Further investigation into cancer redox mechanisms and MDR is thus 
warranted. The molecular mechanisms associated with the chemoresistance mediators 
mentioned herein will be described further along in this introduction.  
 
1.1.1.2 Tumor Acidosis and Metabolism 
As briefly mentioned earlier, lactate, as a by-product of glycolytic tumor cells, is exported 
through MCT4 to the extracellular fluid (ECF) (Draoui & Feron, 2011). Lactate will then be 
progressively shuttled into non-glycolytic cells including endothelial tumor cells to be used 
in oxidative phosphorylation (Ullah et al, 2006). As recognized by A. Weinberg and accepted 
by most of cancer researchers, metabolic reprogramming, distinguished by an increased rate 
of glucose metabolism through glycolysis, is now among the list of the hallmarks of cancer 
(Hanahan & Weinberg, 2011). Since increased glycolysis generates protons as by-products 
at a fast rate (Alfarouk et al, 2014); they tend to accumulate in cancer cells particularly under 
anaerobic conditions where protons cannot react with molecular oxygen to form water 
(Chiche et al, 2010). One of the ways by which tumor cells prevent acidification of 
intracellular pH is through MCT (primarily MCT4) symporter secretion of H+ ions with 
lactate (Draoui & Feron, 2011). Proton extrusion from cancer cells however far exceeds what 
is needed to maintain intercellular pH equilibrium; in fact, proton export from cancer cells 
through both primary and secondary active transport machinery leads to proton gradient 
reversal across the plasma membrane (Alfarouk et al, 2014). Examples of other important 
transporters that mediate proton export from tumors include: V-ATPase proton pump, CAIX 
and sodium-hydrogen exchange 1 (NHE1). Whereas normal tissues have extracellular pH 
(pHe) around 7.4 and intracellular pH (pHi) around 7.2, pHe of tumors in acidosis is typically 
in the range of 6.6-6.8 and pHi in the range of 7.3-7.5 (Barar & Omidi., 2013). As distance 
from blood vessel increases and oxygen tensions drop, pHe also progressively diminishes 
and can go as low as pH 6.0 (Gatenby et al, 2017). Figure 1 depicts some of the physical 
characteristics of the tumor microenvironment. 
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Figure 1. Physical characteristics of the tumor microenvironment 
Depiction of oxygen concentration and pH gradients typical of the tumor microenvironment 
and of the main transporters involved in creating and maintaining tumor acidosis.  
 
It has been argued that exposition to the harsh tumor microenvironment, that includes 
physical factors such as hypoxia and acidosis, selects specifically for tumor cells that display 
extensive proton export machinery (Wojtkowiak et at, 2012). The early stage at which pH 
reversal occurs during carcinogenesis indeed supports the idea that this adaptation plays a 
major role in cancer progression (Reshkin et al, 2014).  In fact, cancer cells that cannot 
regulate their pHi have been shown to be less proliferative and to be less likely to form tumors 
(Ward et al, 2013).  
 
The cancer cell’s response to acidosis remains poorly understood; that is in part because 
findings from past studies have often been confounding. Four major cellular alteration 
features have however stood out in the literature: these are metabolic reprogramming, defense 
against ROS, triggering of autophagy and alterations in endo-lysosomal functions (Lamonte 
et al, 2013; Wojtkowiak et at, 2011 and Zhitomirsky & Assaraf, 2015). 
 
 
 
15 
Reversal of pH gradient in cancer cells has at times been reported to contribute to a switch 
from oxidative phosphorylation to glycolysis just has it has been reported to inhibit 
glycolysis. The foremost claim that the activity of glycolytic enzymes such as lactate 
dehydrogenase and phosphofructokinase-1 (PFK-1) is increased due lo lower intracellular 
pH (Calderon-Montano et al, 2011) whereas the later claim that these genes are down-
regulated as a result of lactic acidosis (Chen et al, 2008). The divergence in these findings 
suggests that distinct cellular machinery must be important in determining the exact 
metabolic response to acidosis; the reason behind these seemingly conflicting results may lie 
with the P53 status of cells being studied. In fact, the P53 protein has been shown to be 
activated by tumor acidosis when functional and to reduce glycolysis through TP53-inducible 
glycolysis and apoptosis regulator (TIGAR) (Lamonte et al, 2013). Additionally, the same 
study showed that P53 activated through acidosis contributes to the activity of two other 
important metabolic pathways: the oxidative branch of the pentose phosphate pathway (PPP) 
necessary for novel ribose synthesis and glutaminolysis which is parallel pathway to 
glycolysis for ATP generation by cancer cells for their elevated energy requirements. These 
two pathways have in common the fact that they both increase the reductive potential of the 
cells, which leads us to the next feature of the acidosis response: defense against ROS. 
Consequently, the overall level of the reducing equivalent nicotinamide adenine dinucleotide 
phosphate (NADPH) is raised and serves to counteract the similar increase in ROS due to the 
stress generated by acidosis (Lamonte et al, 2013). Neutralization of oxidative stress under 
such harsh microenvironmental conditions is necessary to ensure prolonged tumor cell 
survival. Because the P53 dependent changes outlined above also coincide with decreased 
proliferation; it is unclear if the sum of these adaptations plays a role that is tumor suppressive 
or if they contribute to cancer maintenance. Increased pentose phosphate activity as induced 
by acidosis, has previously been associated with brain metastasis (Chen et al, 2007) and 
chemoresistance (Tamada et al, 2012). Importantly, an enhanced reductive potential, 
manifested through increased NADPH replenishment, is a recurring theme with other 
environmental stresses such as hypoxia, glucose deprivation and matrix detachment; it thus 
seems to be a key necessary feature for cancer cell extended survival in the tumor 
microenvironment.  
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Also consistent with the cellular responses to acidosis mentioned above, is the triggering of 
autophagy in response to starvation (Wojtkowiak et al, 2012). It appears that autophagy in 
this context is required as an adaptation to obtain biomolecules from recycled organelles to 
offset metabolic pathways skewed towards catabolism. Alteration of the endo-lysosomal 
compartments is the final feature of the response to acidosis and is closely related to the 
process of autophagy, which entails fusion of lysosomes and phagosomes to form 
phagolysosomes (Hosogi et al, 2014). Different studies in fact suggest tumor acidosis has the 
effect of increasing the number of lysosomes (Avnet et al, 2016), lowering their pH value 
(Zhitomirsky & Assaraf, 2015) and triggering the secretion of lysosomal components into 
the cytoplasm (Steffan et al, 2009). Low lysosomal pH in cancer as well as concomitant 
occurrence of autophagy, and transcription factor EB (TFEB) associated lysosomal 
biogenesis have been linked to prolonged survival under tumor microenvironment stress 
(Salerno et al, 2014) (Zhitomirsky & Assaraf, 2015). Aside from the induction of 
phagocytosis which was already discussed; release of lysosomal components and 
acidification of lysosomal compartments have both been shown to contribute to increased 
survival of tumor cells. Not only does low pHe acts on lysosomal trafficking to increase 
lysosomal exocytosis (Steffan et al, 2009) but it also increases the expression of lysosomal 
proteases such as MMP2, MMP9 and Cathepsin B (Wojtkowiak et at, 2011). In an acidic 
environment, these enzymes promote invasion of the ECM which ultimately also contributes 
to migration and survival. Early reports showed that low pHe can inhibit gap junction (Ruch 
et al, 1990), this finding taken with others that show low pHe favors mesenchymal type-like 
morphology (Amith et al, 2016) suggest that tumor acidosis may play a role in deconstruction 
of cell junctions to further contribute to cancer progression through EMT (Lamouille et al, 
2014).  
 
A steep gradient between the intracellular, extracellular and endo-lysosomal pH has been 
shown to contribute to decreased tumor responsiveness to chemotherapy (Wojtkowiak et al, 
2011) and radiotherapy treatments (Ohtsubo et al, 2001). Although it appears that the 
characteristic of resistance to radiotherapy is mostly linked to the selection of tumor cells 
with defective P53 necessary for adaptation to chronic acidosis (Williams et al, 1999), 
chemoresistance is in turn largely due to the impact that altered pH has on the tissue and cell 
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distribution of the therapeutics themselves. Although the phenomena of impaired tissular and 
cellular distribution of chemotherapy has been observed on several occasions over the last 
few decades, it is only recently that it has become well understood and integrated under one 
overarching framework. The work of Robert J. Gillies and Yehuda J. Assaraf, among others, 
clearly explains how drug distribution is affected through inter-compartment pH gradients. 
Both authors have described a phenomenon coined as “ion trapping” (Wojtkowiak et al, 
2011) that explains how the pH gradient acts as a physiological barrier for drugs or other 
molecules. This phenomenon is of relevance because for many drugs there exists a large 
difference in permeability between the nonionized species of a drug, that are more permeant, 
and the ionized species that can be much more impermeant. In the case of tumor acidosis, 
this phenomenon negatively impacts the capacity of weak base chemotherapeutics to 
effectively permeate through the cell membrane and ultimately reach their intended 
therapeutic target which generally is the cell nucleus. Even the small proportion of weak base 
therapeutics that does penetrate the plasma membrane is not guaranteed to reach the nucleus 
as it is also likely to passively diffuse and become trapped in acidic organelles such as 
lysosomes (Zhitomirsky & Assaraf, 2015). Similarly, molecules that enter cells through 
endocytosis can become entrapped in late endosomes or lysosomes as they are sorted to 
acidic lysosomes through the endo-lysosomal system. This phenomenon however cannot be 
generalized to all chemotherapeutic drugs as some drugs do not have ionizable species, and 
thus pH would not alter their membrane permeability, and others are weak acids which means 
the pH gradient found in tumor acidosis would positively affect their ability to cross the 
plasma membrane (Wojtkowiak et al, 2011). 
 
In fact, based on the chemical structure of each drug and the pH value of cellular 
compartments, it is possible to calculate a partitioning coefficient on a logarithmic scale 
called Log P to describe the distribution of the equilibrium between two phases, one being 
the lysosomes and the other being the cytoplasm. Such calculated Log P values (Zhitomirsky 
& Assaraf, 2015) for common chemotherapeutic drugs are shown in table 2. Drugs with Log 
P values close to 1, such as is the case for doxorubicin and Mitoxantrone, would thus be 
partitioned at a ratio of 10 to 1 in favor of acidic compartments such as lysosomes as opposed 
to the cytoplasm.  
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Table 2: Calculated Log P values for lysosome and cytoplasm partitioning of common 
drugs used for cancer treatment 
Drug Log P Lysosome trapping 
Lapatinib 4.64 [+] 
Gefitinib 3.75 [+] 
Vincristine 3.13 [+] 
Sunitinib 2.93 [+] 
Pyrimethamine 2.75 [+] 
Daunorubicin 1.73 [+] 
Mitoxantrone 1.19 [+] 
Doxorubicin 0.92 [+] 
Pemetrexed 0.73 [-] 
5-Fluorouracil -0.66 [-] 
Adapted with permission from Zhitomirsky & Assaraf, 2015. 
 
Both extracellular space and intracellular compartments have been shown to entrap large 
amounts of chemotherapeutic drugs and to limit their effectiveness (Gerweck, 2006) 
(Zhitomirsky & Assaraf, 2015); the importance of both parallel occurrences should be taken 
into consideration while studying drug resistance since the extracellular space represents a 
much larger volume but lysosomes can reach much lower pH values neighboring pH 5 or 
lower. The phenomenon of “ion trapping” should certainly be taken into consideration in 
selecting the best therapeutic approaches for cancer treatment and for future design of cancer 
therapeutics (Wojtkowiak et al, 2011).  
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1.1.2 Cellular and Molecular Mechanisms of Chemoresistance 
As recognized previously, the tumor microenvironment has a crucial role to play in the 
development of chemotherapy and is clearly an important driver in selecting molecular 
determinants for resistance to chemotherapy. This section provides an overview of specific 
cellular and molecular determinants of chemoresistance as currently recognized in the 
literature.  
 
1.1.2.1 Drug Detoxification 
 Mechanisms of drug detoxification constitute a rather disparate group of processes that all 
share the characteristic of limiting chemotherapeutic drug activity; these processes can take 
an active form where drugs are inactivated by being metabolized or via chemical 
modifications, or they can take a passive form where the necessary activation mechanisms 
are repressed. A prime example of detoxification through a metabolic enzyme would be the 
ability of aldehyde dehydrogenases (ALDH), important biomarkers of CSC to remove 
various toxic aldehydes generated as intermediary metabolites of several chemotherapeutic 
drugs such as cyclophosphamides (Tomita et al, 2016). High expression of ALDH enzymes 
in breast CSCs has been strongly associated with increased resistance to chemotherapy and 
radiotherapy; effects that can be prevented through inhibition of ALDH activity (Croker & 
Allan, 2012). ALDH plays an analogous role in normal stem cells for protection against 
cellular stress and improvement of survival outcomes. Another common mechanism 
contributing to chemoresistance is the conjugation of an anionic group such as glutathione 
(GSH), glucuronate or sulfanate, to chemotherapeutic drugs (Homolya et al, 2003). Such 
chemical modifications transform many drugs in such a way that they become substrates to 
ATP-binding cassette (ABC) transporters that can then export such drugs outside cancer 
cells. These multidrug resistance efflux pumps will be discussed in more details in an 
incoming section. Finally, some chemotherapeutic drugs need to first be activated to become 
cytotoxic; cytarabine needs to undergo a series of phosphorylation to cytarabine triphosphate 
in order to be fully active (Sampath et al, 2006). Cancer cells have been known to adapt to 
cytarabine treatment by downregulating kinases responsible for phosphorylating the drug 
(Bardenheuer et al, 2005).   
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1.1.2.2 Multidrug Resistance Efflux Pumps  
Transporters responsible for drug efflux and development of MDR mostly belong to the ATP-
binding cassette (ABC) protein superfamily that can be subdivided into three subfamilies that 
each have different drug substrate specificities (Glavinas et al, 2004). ATP hydrolysis is the 
general mechanism used by ABC transporters to pump a variety of drugs outside of cells or 
inside vesicular compartments to lower intracellular drug concentrations (Nakanishi and 
Ross, 2012). Fueling ABC transporters represents a large burden for cancer cell metabolic 
needs, as approximately two ATP molecules are consumed to export each molecule of the 
substrate and ATP hydrolysis continues to a certain extent even in the absence of any 
substrate. There is yet no agreed upon naming convention for ABC transporters and each 
protein transporter tends to be referred to under several different names. The P-glycoprotein 
(P-gp), also called MDR-1, is expressed through the ABCB1 gene, whereas the Breast cancer 
resistance protein (BCRP) is expressed through the ABCG2 or MXR gene. These first two 
protein subfamilies mainly recognize and export large positively charged amphiphilic 
compounds whereas the final subfamily of ABC transporters the multidrug resistance 
proteins (MRPs), expressed through the ABCC gene, recognize neutral hydrophobic 
molecules or certain soluble anionic compounds (Glavinas et al, 2004). P-gp is known to 
transport and to lead to resistance against drugs such as vinca alkaloids, anthracyclines and 
paclitaxel (Gottesman et al.,2002). MCRP also transports anthracyclines and also recognizes 
topoisomerase inhibitors and mitoxantrone. Finally, MRP1 can transport many classes of 
chemotherapeutic compounds including vinca alkaloids and anthracyclines, although these 
compounds often need to have first been conjugated with glutathione (GSH), glucuronide or 
sulfate (Yin and Zang, 2011). There is evidence that certain selective pressures, such as 
cancer drug exposition, lead to differential P-gp localization (Petriz et al, 2004), which when 
targeted to the lysosomal membrane can lead to lysosomal drug sequestration (Chapuy et al, 
2008). 
 
1.1.2.3 Defects and Imbalances in Cell Death and Survival Pathways 
There exist a multitude of adaptations that cancer cells may undergo involving modifications 
to cell death and survival pathways that ultimately result in increased resistance to 
chemotherapy. As these have been extensively described in the literature, to summarize these 
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adaptations could represent an entire review on its own; as such the current section merely 
seeks to acknowledge their vast role in EMDR and to provide a few examples. Of course, it 
isn’t possible to discuss alterations to apoptotic pathways without mentioning selection of 
inactivating mutations to P53, s staple of apoptotic proteins that has wide ranging impacts on 
cellular function and that is correlated with de-novo resistance to doxorubicin in breast cancer 
(Arnason and Harkness, 2015). Alternatively, selective pressures may by contrast select for 
activating mutations to anti-apoptotic proteins such a B cell lymphoma 2 (Bcl-2) protein 
(Teicher, 2006). In many cases the effects of environmental pressures such as hypoxia and 
high pHi can prevent activation of G1/S checkpoint and activate checkpoint kinases 1 & 2 
(ChK1 & ChK2) that coordinate the DNA damage responses with the cell cycle to facilitate 
progression through the G2 phase (Maugeri-Saccà et al, 2011). Hypoxia can also negatively 
affect several DNA damage response pathways including homologous recombination, non-
homologous end joining and mismatch repair (Bristow and Hill, 2008); hypoxia may also 
result in telomere shortening and chromosomal instability (Verdun and Karlseder, 2007). 
Modifications to cell death and survival pathways may result from selection by exposition to 
a particular drug; however once acquired these adaptations are likely to cause resistance to a 
wide-ranging spectrum of drugs. 
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1.1.2.4 Compartmentalization and the PSS Model 
The rationale behind the cellular mechanism of weak base therapeutics compartmentalization 
has previously been covered through the explanation of the lysosomal ion-trapping 
phenomenon. It must be noted that ion-trapping is in no way exclusive to lysosomes as it has 
also been observed to occur in other acidic cellular compartments such as endosomes (Lee 
& Tannock, 2006). Description of ion-trapping as a contributing factor to chemoresistance 
was first described in 1996 where following the initial observation that doxorubicin resistant 
MCF7 breast cancer cells have more acidic intra-vesicular compartments than their 
doxorubicin sensitive counterparts, the protonation, sequestration and secretion (PSS) model 
was proposed by Sanford Simon (Schindler et al, 1996) to rationalize increased resistance to 
doxorubicin. The first two step of the process are consistent with ion-trapping as previously 
described and the third step refers to secretion through efflux pumps or through simple 
exocytosis.  
 
Cellular or molecular mechanisms leading up to compartmentalization of weak base 
therapeutics by cancer cells remain to be described. Doxorubicin is often used as model drug 
in experimental design involving microscopy as it has the advantageous property of emitting 
natural fluorescence (Lucien et al, 2014). This property allowed our laboratory to observe 
doxorubicin extranuclear spots reminiscent of the ion-trapping phenomenon (Figure 2) in 
HT1080 cells (Lucien et al, 2017). Similar findings had previously been obtained by other 
researchers (Lee & Tannock, 2006), but our results were the first indication that the tumor 
microenvironment, in this case hypoxia, could consistently increase drug sequestration. The 
current study will explore ramifications of this key finding and how improved understanding 
of this apparent mechanism of chemoresistance can be exploited in a novel therapeutic 
approach. 
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Figure 2. Subcellular localization of doxorubicin under hypoxia 
A) Representative images of sub-cellular distribution of doxorubicin in live HT1080 cells 
under normoxia and hypoxia. The nucleus was stained by incubating cells with Hoechst 
33342. Cells at 1% O2 were kept under hypoxia for 4h. B) The percentage of doxorubicin 
present at the nucleus was quantitated by using the overlapping signal from Hoechst 33342. 
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1.2 Regulators of pH Equilibrium in Tumor Cells 
Distinct metabolic signatures of tumor cells and increased in energy demands contribute to 
create a harsh tumor microenvironment characterized by highly acidic ECF. These conditions 
exert major selective pressures on tumor cells that force them to adapt to such adverse 
variations. Expression and activity of a number of proton channels and exchangers can be 
modulated by cancer cells in order to survive tumor acidosis. Regulators of tumor cell pH 
equilibrium and their known functions in the process are described below.  
 
The MCT protein family responsible for the transport of monocarboxylate substrates such as 
pyruvate, lactate and ketone bodies is constituted of 14 known members, but only MCT1-4 
have been confirmed to have a proton linked transporter activity (Halestrap, 2012). Although 
each of these transporters may contribute to either efflux or influx of protons, MCT1 was 
shown to be mostly located in well oxygenated regions of xenograft tumors where it is 
involved in proton influx (Sonveaux et al, 2008) whereas MCT4 is better adapted to facilitate 
efflux (Dimmer et al, 2000). The activity of these transporters is driven by the concentration 
gradient of the monocarboxylate substrates, such as lactate, on which proton transport is 
dependent (Wilson et al, 2009). In the case lactate and proton transport, lactic acid is 
transiently formed during transport across the plasma membrane to be readily dissociated in 
the ECF. Although MCT1 and MCT4 have by far received the most attention in cancer 
research, MCT2 has also been found to be expressed in brain, prostate and colon cancer 
(Spugnini et al, 2015). Evidence of import and export duality of the MCT transporters in 
tumor goes a long way to support the theory of metabolic symbiosis in tumors. Interestingly, 
in-vivo inhibition of MCT1 was shown to limit tumor growth (Sonveaux et al, 2008). This 
finding may be a result of lactate metabolism being replaced by glycolysis in MCT1 
expressing cells which would limit the pool of fuel sources the tumor as a whole can use. 
Several MCT inhibitors are currently being developed or undergoing clinical trial; one 
example would be the 7ACC2 compound which acts as a specific inhibitor of lactate import 
by MCT1 and MCT4 transporters (Draoui et al, 2014). Another family of proteins that is 
critical for inter and intracellular pH regulation is that of carbonic anhydrases (CAs); a family 
of 14 known zinc metalloenzymes that catalyze the reaction from one molecule of carbon 
dioxide and of water, two oxidative phosphorylation by-products, to a bicarbonate anion and 
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a proton (Supuran, 2008). The majority of CAs is needed for important physiological 
functions with the notable exceptions of CAIX and CAXII (Neri & Supuran, 2011). Both 
CAIX and CAXII are primarily expressed within tumors and are known to be determinant 
factors in establishing the pH gradient reversal often observed in tumors (Vullo et al, 2003). 
Expression of CAIX or CAXII in tumors is sometimes correlated with increased expression 
and activity of chloride couple bicarbonate transporters (Cl-/HCO3-) that allow recapture of 
HCO3- that further exacerbates the pH gradient across tumor cell membranes by raising pHi 
(Morgan et al, 2007). CAIX and CAXII differ where the tumor localization of the former is 
highly concentrated in hypoxic regions or necrotic tumor core, and the later is more evenly 
distributed across the tumor (Tafreshi et al, 2012). Of all the tumor associated pH regulators 
presented in the section, CAIX and CAXII may well be the proteins associated with most 
advanced stage of cancer as described in the EMDR model. In fact, these two CA enzymes 
are associated with poor clinical outcomes and have been identified as having important roles 
for most stages of tumor progression; namely tumor growth, tumor cell survival, acidification 
of the ECF, invasion, initial stages of the metastatic cascade and resistance to chemotherapy 
(Benej et al, 2014). Attempts to inhibit CA activity to prevent cancer progression have 
generally been rendered more challenging by the fact that many tumor cells models respond 
to CAIX inhibitors by compensating with expression of CAXII (Lou et al, 2011). The 
exception is breast cancer for which CAIX is solely expressed in many models.  
 
Chloride channels (ClC) and Cl-/H+ antiporters constitute a diverse set of proteins that share 
the characteristic of transporting chloride ions and protons and of regulating intracellular pH 
and cell volume (Picollo and Pusch, 2005). ClC-3 in particular, has been shown to be highly 
expressed in metastatic carcinomas, was associated with poor survival outcomes and was 
suggested to be an interesting therapeutic target (Xu et al, 2015). This protein superfamily 
has however received very little attention when compared with the other transporters 
mentioned.   
 
The vacuolar ATPase (V-ATPase) is a proton pump primarily located at the surface of 
intracellular vesicles (Sennoune et al, 2004) that may also intermittently linger within the 
plasma membrane through recycling of endosomal/lysosomal compartments (Steffan et al, 
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2009). V-ATPase is a large complex multi-subunit protein that actively pumps hydrogen ions 
(Forgac, 2007) from the cytoplasm into vesicles (or into the ECF). As V-ATPase activity and 
expression is elevated in many tumors and endosomal turnover is accelerated by low pHe, V-
ATPase is believed to play an important role in preventing cytoplasmic acidification and thus 
enabling cellular adaptation to the harsh tumor microenvironment. The coupling of V-
ATPase with endosomal trafficking (Martìnez-Zaguilán et al, 1999) results in indirect proton 
extrusion from vesicle recycling, an event that exacerbates the pH gradient across the plasma 
membrane of tumor cells by lowering pHe and contributing to tumor hallmarks such as 
invasion, metastasis (Feng et al, 2013) and multidrug resistance (von Schwarzenberg et al, 
2014) as previously described. Through regulation of endosomal pH, expression and activity 
of V-ATPase is also believed to affect the cellular functions of endocytosis and autophagy 
(Spugnini et al, 2015); and to have an impact on ion-trapping. For these reasons, and the fact 
that V-ATPase expression is particularly elevated in highly metastatic breast cancer cells, 
inhibition of V-ATPase has been seen as a promising therapeutic strategy for many years; 
however clinical trials of various inhibitors have either revealed high toxicity or limited 
efficacy to date (Perez-Sayans et al, 2012).  
 
1.2.1 Plasmalemmal Sodium/Hydrogen Exchangers 
The SLC9 gene family is a protein family that is expressed in organisms ranging from 
prokaryotes to mammals; it is composed of a total of 13 known Na+/H+ exchangers (NHE) of 
which nine closely related exchangers form the distinct SLC9A subfamily (Fuster and 
Alexander, 2014). Little is currently known of the remaining four members of the SLC9 
family, these exchangers are outside the scope of the current discussion. Of the nine closely 
related SLC9A family members, five are primarily localized at the plasma membrane 
whereas four are usually located on intracellular membranes. Although tissue distribution 
(Table 3) and functional roles of plasmalemmal NHE exchangers vary significantly, all of 
these exchangers have a common function in regulating pH homeostasis and cell volume 
(Donowitz et al, 2013). Each NHE exchanger share a common general structure that is 
formed of 12 transmembrane domains forming a channel capable of binding and 
translocating Na+ and H+ ions. NHE’s are often N or O-glycosylated on extracellular loops 
and contains a long C-terminal cytoplasmic tail that serves as a scaffold for intracellular 
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signaling (Counillon et al, 1993). Post-translational modification of NHE C-terminals can 
impact the transporter’s activity, target the transporter to discrete areas of the membrane or 
influence turnover dynamics (Fuster and Alexander, 2014).  
 
Table 3: Localization and tissue distribution of human NHE plasmalemmal proteins 
(Adapted with permission from Fuster & Alexander, 2014, Springer License n°  
4107700591546 and with permission from Zhao et al, 2016, Elsevier Science and Technology Journals License 
n° 4107711153866.) 
 
Because of it’s ubiquitous expression, NHE1 is mostly recognized for it’s housekeeping 
functions. Its discrete localization at the plasma membrane may shift between different cell 
types, but its general function remains to control intracellular pH homeostasis by allowing 
electroneutral exchange through H+ leakage and Na+ influx driven by a strong 
electrochemical gradient.  Na+ influx is followed by Cl- and H2O intake which together act 
as an important mechanism to prevent cell shrinkage. Discrete plasma membrane 
localizations in polarized epithelial cells, cardiac myocytes and fibroblasts have all been 
associated with further functional roles in these cell types. In acinar cells of the parotid gland, 
NHE family member 
(protein/gene name) 
Cellular localization Tissue distribution 
NHE1/SLC9A1 
Plasma membrane 
Basolateral membrane of 
epithelial cells 
Ubiquitous 
NHE2/SLC9A2 
Plasma membrane 
Apical membrane of 
epithelial cells 
Gut, skeletal muscles, 
kidney, brain, uterus testis, 
heart and lung.  
NHE3/SLC9A3 
Plasma membrane 
Recycling endosomes of 
epithelial cells 
Kidney, gut, heart, brain 
and lung. 
NHE4/SLC9A4 
Plasma membrane 
Basolateral membrane of 
epithelial cells 
Gut, kidney, brain, uterus 
and skeletal muscles. 
NHE5/SLC9A5 
Plasma membrane 
Recycling endosomes and 
synaptic vesicles 
Brain, testis, spleen and 
skeletal muscles.  
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NHE1 was demonstrated to be important for fluid secretion and NaCl absorption (Park et al, 
2001). In cardiac myocytes, the localization of NHE1 in microdomains with intercalated 
disks and T-tubules is believed to affect the activity of the pH sensitive ryanodine-sensitive 
Ca++ release channels by modulating Ca++ sensitivity of these channels (Xu et al, 1996). 
Thirdly, there is evidence that NHE1 concentrates to sites of focal adhesions in fibroblasts 
along the border of the lamellipodia which is believed to be important in cellular migration 
and chemotaxis (Denker et al, 2000). Most important in the context of this review is the 
uniquely recognized role of NHE1 in cancer progression among plasmalemmal NHE’s. As 
for other regulators of the pH equilibrium of tumors, NHE1’s function of alkalinizing 
intracellular pH favors prolonged survival of cancer cells, increased proliferation and is seen 
as a factor of malignant transformation (Reshkin et al, 2000). By concentrating at the leading 
edge, especially in the case of breast cancer, NHE1 contributes to increased proteinases 
degradation of the ECM and subsequently cell migration and metastasis (Denker, 2002).  
 
As shown in table 3, NHE2-4 are each associated with a narrower tissue distribution than 
NHE1 and each serve for more specialized cellular functions. NHE2 is predominant in the 
gut where it is located in the apical membrane of epithelial cells and appears to be necessary 
for proper differentiation of these tissues (Schultheis, 1998). NHE3 has predominantly been 
studied for its role in renal physiology where it is critical for sodium reabsorption from the 
proximal tubule, regeneration of bicarbonate buffer in the proximal tubule and water 
reabsorption (Li et al, 2013). NHE4 also appears to play distinct role in the gut and kidneys 
although these are still poorly characterized. NHE5 is primarily expressed in the brain where 
it is important for dendritic spine growth and Trk tyrosine kinase trafficking (Diering et al, 
2013). NHE5 and NHE3, which are closely related homologs, have the particularity of 
recycling between the cell surface and endosomes (Fuster and Alexander, 2014).  
 
1.2.2 Intracellular Sodium/Hydrogen Exchangers 
The four intracellular Na+/H+ exchangers, form an evolutionarily distinct subgroup within the 
larger NHE protein family. They are thus all closely related homologs that are ubiquitously 
expressed in human tissues and that are primarily located in organellar membranes rather 
than at the cell surface (Zhao et al, 2016). Of those exchangers, NHE6 and NHE9 are both 
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commonly located in distinct but overlapping endosomal compartments (Table 4) whereas 
NHE7 and NHE8 are usually located in the trans and medial Golgi respectively. Besides 
sharing a similar cellular localization, NHE6 and NHE9 are also highly expressed in the brain 
and neuronal cells more particularly. Inactivating mutations in either exchanger is also 
associated with neurological diseases (Table 4).  
 
Table 4: Cellular location and diseases associated with human NHE intracellular  
proteins 
(Adapted with permission from Fuster & Alexander, 2014, Springer License n°  
4107700591546 and with permission from Zhao et al, 2016, Elsevier Science and Technology Journals License 
n° 4107711153866.) 
 
The fact that NHE proteins are commonly expressed in the brain should not come as a 
surprise as many neural functions such as membrane voltage, ligand-gated ion channels, 
neurotransmitter systems, intracellular signal transduction and gap junction communication, 
are dependent on precise pH regulation (Takahashi and Copenhagen, 1996). Alkaline ECF is 
generally correlated with increased neural excitability, while acidic ECF has the opposite 
effect (Ruusuvuori and Kaila, 2014).  Little is currently known of the physiological roles of 
NHE7 whereas NHE8 is believed to have largely redundant roles with NHE3 as it has a 
comparable tissue distribution in the kidneys and gut; and KO mice of the two exchangers 
display similar phenotypes (Xu et al, 2013). NHE8 however seems to play a larger role in 
NHE family member 
(protein/gene name) 
Cellular localization Known associated diseases 
NHE6/SLC9A6 Sorting and recycling 
endosomes 
X-linked Angelman-like condition 
Christianson syndrome 
Autism 
NHE7/SLC9A7 TGN  Cancer 
NHE8/SLC9A8 Medial Golgi to TGN None 
NHE9/SLC9A9 Late endosomes 
Autism 
Epilepsy 
ADHD 
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neo-natal individuals whereas the expression and activity of NHE3 is more important in 
adults (Becker et al, 2007).  
 
The endosomal/lysosomal system is composed of fluid membrane endosomal compartments 
that gradually lean toward increasingly more acidic pH balance as it goes form early or 
recycling endosome (≈ pH 6.3-6.5), to late endosome (≈ pH 6.0) and lysosomes (≈ pH 5.0-
5.5) (Ohgaki et al, 2011). The secretory pathway also forms increasingly more acidic 
compartments as it goes for the endoplasmic reticulum (ER, ≈ pH 7.2), to the Golgi (≈ pH 
6.0-6.7) and to secretory vesicles (≈ pH 5.2-5.7). The finely tuned pH balance across these 
sub-cellular compartments is somewhat influenced by activity of V-ATPase but is more 
importantly determined by NHEs and chloride coupled proton exchangers (Steinberg et al, 
2010). Maintenance of that pH balance is critical for endosomal pathway trafficking, 
dissociation ligand-receptor complexes and calibration of the enzymatic activity, such as that 
of lysosomal proteases (Ohgaki et al, 2011).  
 
NHE6 is known to affect pH homeostasis in endosomes by pairing H+ leakage with either 
Na+ or K+ entry. Although ion balance in endosomal compartments is likely also functionally 
relevant, it remains largely misunderstood to date. Inactivating mutations of NHE6 have been 
shown to result in over-acidification of endosomes, in a few cells models including polarized 
hepatoma HEPG2 cells (Ohgaki et al, 2010) and to disturb many of the functions dependent 
on proper pH regulation as described above (Ohgaki et al, 2010). In HeLa cells however, 
inhibition of NHE6 did not significantly alter endosomal pH as loss of NHE6 was 
compensated with expression of NHE9 (Roxrud et al, 2009). 
 
Of the four intracellular NHE, there have been reported cases of NHE7 and NHE9 
contributing to cancer progression. NHE7 was found to enhance cell-to-cell adhesion, 
invasion, anchorage-independent growth and to induce tumor formation and growth in an 
MDA-MB-231 cell model (Onishi et al, 2011). Alternatively, NHE9 was observed to 
contribute to cancer progression in glioblastomas by alkalinizing endosomes and 
preventing EGFR degradation, which caused sustained oncogenic signaling through MAPK 
and Akt pathways (Kondapalli et al, 2015). 
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Unlike for some of the plasmalemmal NHE’s, for which many protein interactions and 
modifications of the C-terminal cytoplasmic tail that modulate exchanger activity and 
localization have been well characterized, understanding of how intracellular signaling 
affects intracellular NHE’s is largely lacking.  
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1.3 The Versatile RACK1 Scaffolding Protein 
The RACK1 protein, also known as guanine nucleotide-binding protein subunit beta-2-like-
1 (GNB2L1), is an ubiquitous protein expressed by most eukaryotic organisms (Gibson, 
2011). It was originally named RACK1 for receptor for activated C kinase 1 as it was first 
discovered as an interaction partner of protein kinase C (PKC). As is typical of proteins of 
the Tryptophan-Aspartate 40 (WD40) repeat family, RACK1 can be recognized by it’s 
distinct 7 bladed beta-propeller structure (Figure 3) (Li and Xie, 2015). This particular shape 
is ideal for RACK1's role as a scaffolding protein as it allows it to interact with multiple 
partners at once as part of large protein complexes. These interacting proteins may serve a 
myriad of cellular functions and be present in diverse cellular localizations.  In some cases, 
several WD40 repeat proteins can interact with each other (including RACK1 oligomers) to 
form even more intricate protein complex structures (Chen et al, 2004). 
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Figure 3. Three-dimensional structure of the RACK1 scaffold protein 
A) Cartoon representation of the RACK1 protein and its 7 WD repeat domains each shown 
in a different color. B) Surface representation of the RACK1 protein and its 7 WD repeat 
domains each shown in a different color. Images captured with PyMOL Molecular Graphics 
System, Version 1.8 Schrödinger, LLC. 
 
Aside from simply acting as a scaffold for protein complexes, RACK1 was proposed by Li 
and Xie to be capable of influencing its binding partners in four distinct ways. RACK1 is 
capable of “shuttling partners from one site to another, modifying the activity of the partners, 
changing intermolecular interaction (enhancing association/dissociation), and modulating 
the stability of binding proteins” (Li and Xie, 2015). An example of protein shuttling would 
be the matching shift in localization of RACK1 and PKC isozymes that occurs in several cell 
types following the activation of PKC (Ron et al, 1999). Binding of RACK1 and PKC, which 
requires PKC to be in an active conformation (Adams et al, 2011), has also been reported to 
result in increased PKC kinase activity (Ron et al, 1994).  
 
Due to sheer number of direct or indirect interaction partners that have been associated with 
RACK1 throughout the years, the current section will need to be narrowed down to 
observations that have been made linking RACK1 to pH regulators and to the ambivalent 
role RACK1 plays in cancer. There have been multiple reports of RACK1 acting either as a 
pro-carcinogenic or as an anti-carcinogenic agent to date. Examples include the detailed 
molecular mechanisms that describe how RACK1 promotes or impairs proliferation or how 
it can tip anti- and pro-apoptotic signaling one way or another (Li and Xie, 2015). The current 
consensus in the research community is that the role RACK1 plays in relation to cancer is 
context dependent of the diverse signaling pathways it can interact with in different cell 
models.  
 
Dr. Kanazawa and his research group, showed with a yeast-two-hybrid screening experiment 
that RACK1 was able of interacting with NHE6, NHE7 and NHE9 (Ohgaki et al, 2008). The 
WD40 domains 5-7 were sufficient to mediate those protein-protein interactions. The same 
study showed that RACK1 knockdown in Hela cells had the impact of elevating recycling 
endosome pH and of reducing basal cell surface levels of NHE6 in this cell model. 
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Figure 4. Sequences of interaction with RACK1 amongst human NHE proteins 
Amino acid sequences of human NHE identified by Ohgaki et al (2008) to interaction with 
RACK1 protein.  
 
 
Additionally, recombinant maltose binding protein (MBP) fusion protein pull-down 
experiments identified a sequence of 60 to 62 amino acids (the sequence in NHE9 is shorter 
by two residues) necessary for that interaction to occur (Figure 4) (Ohgaki et al 2008/2010).  
The team concluded that RACK1 can influence the distribution of NHE6 between endosomes 
and the cell surface to regulate endosomal pH. 
 
The four influences RACK1 can have on interacting partners provide some clues to how 
RACK1 may help modulate NHE6 protein levels. An examination of reported examples of 
RACK1 involvement in anchorage of plasma protein is needed to gain a more complete 
understanding of how RACK1 may influence cellular pH regulation. The most detailed of 
such examples, is the interaction of RACK1, demonstrated in several cancer cell lines, with 
the cytoplasmic tail of IGF1R, which is required for the recruitment of proteins necessary for 
IGF1R signaling (Zhang et al, 2006). These proteins include Shc, insulin receptor substrate 
(IRS) 1/2 and activator of transcription factor 3 (Stat 3). Another prominent example of 
regulation of surface levels of a plasma membrane ion channel by RACK1 is that of cystic 
fibrosis transmembrane regulator (CFTR) in secretory epithelial cells (Smith et al, 2013). 
Although this particular study showed that RACK1 does not interact directly with CFTR, it 
also showed that RACK does interact directly with filamin A (FlnA), a cytoskeletal adaptor, 
and that this interaction is necessary to maintain cell surface levels of CFTR. 
 
 
 
35 
Another interesting insight into RACK1 signaling can be obtained from examining protein 
interactions from similar WD40 proteins. One such protein is the Gβ1 protein which is critical 
for G-protein coupled receptor (GPCR) signaling and which shares 57% homology with 
RACK1 in humans and is also composed of seven WD40 repeat domains (Chen et al, 2004). 
The Gβ1 protein interacts with Gα in a strong transient interaction in GPCR and, as is typical 
of strong transient interactions, is triggered to dissociate upon activation of the receptor. It is 
conceivable that RACK1 undergoes similar binding patterns with its many interaction 
partners.  
 
With regard to metastasis and chemoresistance, RACK1 does seem to play a somewhat 
clearer role. RACK1 is necessary for stabilization of intermediate filament protein vimentin 
and focal adhesion kinase (FAK) that play an important role for endothelial cell invasion in 
the early stages of the metastatic cascade (Dave et al, 2013). RACK1 was also shown to 
colocalize with NHE5 at points of focal adhesions, which further hints at a role in cell 
migration (Ichiro et al, 2006). Unlike for the interaction between RACK1 and intercellular 
NHE exchangers, the binding domain for NHE5 was found to be contained in WD40 domains 
1-3. Although, the NHE5 sequence interacting with RACK1 was not specifically identified, 
it would not correspond to the same sequence identified in intracellular NHE exchangers 
since that portion of the cytoplasmic tail is missing from NHE5.  Finally, RACK1 was 
reported to control cell surface level of ABCG2 receptor in HeLa although the exact 
molecular mechanism was not elucidated (Ikebuchi et al, 2013). This same study showed 
that RACK1 overexpression induced resistance to mitoxantrone which was reversed upon 
treatment with the fumitremorgin C selective ABCG2 inhibitor. 
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Hypothesis 
Following the initial observations described previously, we formulated the hypothesis that 
the localization of NHE6 plays an important role in both the endosomal/lysosomal 
acidification and loss of nuclear doxorubicin triggered by hypoxia. Additionally, we 
hypothesize that a direct protein-protein interaction with the scaffold protein RACK1 is 
critical for the development of a pH-dependent chemoresistance phenotype. 
Our study was divided into two successive steps each associated with a main objective and a 
set of sub-objectives. 
 
Objective #1: To evaluate the effect of hypoxia on the interaction of NHE6 with RACK1 in 
cancer cells, and to assess the impact of that interaction on pH-dependent chemoresistance. 
• To assess the interaction between NHE6 and RACK 1 under hypoxia. 
• To construct a peptide that can compete with the interaction of NHE6 with RACK1 
and thus serve as a specific tool to evaluate the biological impacts of that 
interaction. 
• To assess the effect of the NHE6-RACK1 competing peptide on pH-dependent 
chemoresistance. 
• To investigate the upstream mechanism leading to NHE6/RACK1 interaction under 
hypoxia. 
 
Objective #2: To identify key amino acid residues responsible for NHE6-RACK1 
interaction. 
• To determine the degree of conservation of residues within the RACK1 binding 
domain of human NHE6. 
• To perform an in-silico analysis of the bio-chemical properties of the RACK1 
binding domain. 
• To locate the site of NHE interface at the surface of RACK1. 
• To perform a protein-peptide docking protocol to approximate interface affinity 
between RACK1 binding sites and NHE6-derived peptides.
2. MATERIAL AND METHODS 
2.1 Antibodies and Reagents 
All antibodies used for co-immunoprecipitation (IP) or immunofluorescence (IF) were 
acquired from commercial suppliers. The rabbit monoclonal antibody against NHE6 was 
obtained from Abcam (Cambridge, UK). The anti-human influenza hemagglutinin (HA) 
epitope tag mouse monoclonal antibody was purchased from Covance (Princeton, NJ). 
Mouse and rabbit antibodies directed against RACK1 were respectively obtained from BD 
Biosciences (Franklin Lakes, NJ) and Cell Signaling Technologies (Danvers, MA). A mouse 
antibody for α-Tubulin was acquired from Sigma Aldrich (St. Louis, MO). Nigericin used 
for pH calibration solutions was also obtained from Sigma Aldrich. Mouse anti-EEA1 and 
anti-Rab5 were both purchased from Santa Cruz Biotechnology (Dallas, TX). All Alexa 
Fluor secondary antibodies, 4’,6’-diamidino-2-phenylindole (DAPI), Hoechst 33342, 
lysotracker, pyranine (HPTS), EZ-LinkTM Sulfo-NHS-SS-Biotin, Streptavidin Texas Red 
conjugate, CellROX Green Reagent and Alexa-conjugated Transferrin were obtained from 
Thermo Fisher Scientific (Waltham, MA). Doxorubicin was obtained from the CHUS 
Fleurimont hospital pharmacy (Sherbrooke, Qc). 
 
2.2 Cell Culture and Hypoxic Incubation 
Adherent HT1080 fibrosarcoma cells (ATCC) were cultured in 15 cm petri dishes with 
Eagle’s minimum essential medium (EMEM) while adherent MDA-MB-231 breast cancer 
cells were cultured with Dulbecco’s Modified Essential Medium. Culture media were 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 40μg/ml gentamycin. 
For cell subculture, a 0.25% Trypsin and 0.53mM EDTA phosphate-buffered saline (PBS) 
solution was used to detach the cells. A sub-culture ratio ranging from 1:4 to 1:10 was used 
for HT1080 cells and from 1:2 to 1:4 for MDA-MB-231 cells. Depending on the degree of 
confluence, the culture medium was, every 2-3 days, either replaced for fresh culture medium 
or the cells were passaged into new petri dishes. For the cell freezing procedure, freeze 
medium was made from fresh culture medium further supplemented with 10% FBS (for a 
total of 20% FBS) and with 10% dimethyl sulfoxide (DMSO). Cells (1-2 x106 depending on 
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the cell type) were aliquoted into CryoTubes and frozen at -80°C. Cell aliquots were 
subsequently transferred into liquid nitrogen for long term storage. Cell culture under 
normoxic environment was carried into a 37°C humidified atmosphere of 21% O2 and 5% 
CO2. Cell culture under hypoxic environment was carried into an In Vivo2 400 hypoxia 
workstation (Ruskinn) with identical conditions except for 1% O2 (depleted oxygen was 
replaced with nitrogen). Whenever it is mentioned in a protocol that cells are placed under 
hypoxia, corresponding cells are treated in the same manner under normoxia. Live cells were 
visualized using an Olympus FV1000 (Olympus, Tokyo, Japan) scanning confocal 
microscope and placed in a humidified chamber with controlled temperature (37°C) and CO2 
(5%).  
2.3 Plasmid Constructs and Expression in Human Cell Lines 
peGFP-N3-NHE6 variant 2 was a kind gift from Dr Hiroshi Kanazawa. Whenever amino 
acid sequence numbers are used to describe amino acids position in the current thesis, they 
will thus always refer to variant 2 of human NHE6.  In order to construct the pcDNA3-
HA/NHE6 plasmid, the segment corresponding to NHE6 coding sequence was removed from 
peGFP-N3-NHE6 using the BamH1 and EcoR1 restriction sites and spliced into pcDNA3-
HA generously provided by Dr Jean-Luc Parent. The NHE6527-588 segment was amplified 
from peGFP-N3-NHE6 using the following pair of primers: 
 forward 5’-ATGCGGATCCACCAAAGCAGAGAGTGCTTG-3’ 
 reverse 5’-GCATGAATTCTTAATCATCATCTTTCAACTGTT-3’ 
The resulting fragment was subsequently inserted into pcDNA3-HA to yield the vector 
pcDNA3-HA/NHE6527-588 which was then used for stable transfection. HT1080 cells were 
transfected with polyethylenimine (PEI, MirusBio, PA) whereas MDA-MB-231 cells were 
transfected with Lipofectamine 2000 (Sigma Aldrich). Cells were then selected using 
Geneticin (G418) at a concentration of 400μg/ml in the case of HT1080 cells and at a 
concentration of 2mg/ml in the case of MDA-MB-231 cells. peGFP-N3-NHE6 was 
transfected into HT1080 cells with PEI and into MDA-MB-231 cells with Lipofectamine 
2000 for transient expression of eGFP-NHE6 and fluorescence microscopy visualization. 
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2.4     Intracellular pH Measurement 
The pH sensing ratiometric dye pyranine (HPTS) was used for pH measurement of the 
endosomal/lysosomal compartments either alone or in conjugation with 5-(and-6)-Carboxy 
SNARF-1 used for pH measurements of the cytoplasm; both pH indicators were purchased 
from Life Technologies. Briefly, cells were cultured into 35mm petri dishes (BD 
Biosciences) to which was added 1mM of HPTS for a total of 16h for HT1080 cells and 40h 
for MDA-MB-231 cells (in which endocytosis is slower). Two hours prior to hypoxic 
stimulation, culture medium was replaced with serum-free medium for starvation and fresh 
HPTS was added. Cells were then placed at 1% O2 or left at 21% O2 for a total of 4h. When 
cytoplasmic pH measurement was performed, 5 μM SNARF-1 was added for the final 20 
min of the 4h incubation. Serum-free medium that had been equilibrated for 6h into the 
hypoxia workstation was used to wash the excess HPTS and SNARF-1 probes from cells 
incubated in hypoxia. Live cells were then brought to the confocal microscope where and the 
petri dish containing the cells was mounted directly in the petri dish imaging chamber under 
a controlled environment. Pictures were rapidly taken using a 40x objective and fluorescence 
emission was recorded to be later converted into pH values. Further details of the technique 
have been described in a previous study (Lucien et al., 2014). 
 
2.5 Intracellular Localization of Doxorubicin 
Adherent HT1080 cells were seeded onto 25mm diameter glass coverslips (Thermo Fisher 
Scientific) placed inside 35mm petri dishes and allowed to grow to a confluence of 
approximately 20%. EMEM culture medium was replaced with 0.5% FBS medium for an 
overnight starvation. The next morning, a 50ml falcon was filled with 0.5% FBS EMEM and 
placed into the hypoxia workstation for 6h to equilibrate the O2 concentration. Cell culture 
medium was changed for fresh EMEM and cells were either kept in the incubator or placed 
into the hypoxia workstation for 4h. Following 1h of hypoxic incubation, doxorubicin was 
added to the culture medium at a concentration of 2μM. Hoechst 33342 was then added 1h30 
min later at a concentration of 5 μg/ml. After cell exposition to doxorubicin for 2h, the cells 
were washed with fresh 0.5% FBS EMEM and incubated for 1h. Cells were washed once 
again immediately before visualization; the glass coverslip on which cells were cultured was 
transferred to a rack adapted to the microscope platform and 1ml of EMEM was added to the 
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chamber atop the cells. Live HT1080 cells were brought to the confocal microscope and the 
rack was placed into the controlled environment chamber. A 63x objective was used with 
immersion oil to visualize the cells; a 405nm diode laser was used to excite the Hoechst stain 
fluorophore and a 543nm helium neon laser to excite the doxorubicin fluorophore. 
Doxorubicin light emission was collected between wavelengths of 580nm and 625nm.  
Typically, 5 pictures were taken for each petri dish with 2-3 cells per field thus yielding 10-
15 cells to be analyzed for each condition. Image analysis was performed using the Fluoview 
software package. For both probes, intensity thresholds were set to remove any background, 
these thresholds were maintained constant for the analysis of all series of pictures in the 
experiment. For each cell, the percentage of nuclear doxorubicin was calculated by doing a 
ratio of doxorubicin signal intensity co-localized with positive Hoechst pixels over the total 
doxorubicin intensity. Average nuclear doxorubicin was then calculated for each series 
(corresponding to one petri dish and one experimental condition).  
 
2.6  Immunofluorescence 
Adherent cells were cultured on 15mm diameter glass coverslips (Thermo Fisher Scientific) 
inside well plates. Following the appropriate treatments, cells were fixed in 1% 
paraformaldehyde (PFA) dissolved in PBS, for 10 min at room temperature. From this step 
onward, cells were kept from direct exposure to light. Afterwards, cells were permeabilized 
in 0.05% Saponin (Sigma Aldrich) for 20 min and blocked in 2% bovine serum albumin 
(BSA) for 30 min; both steps were carried at room temperature and both compounds were 
dissolved in PBS. Cells were incubated with the primary antibody for 1h30 min at room 
temperature and, following a quick wash step, were then incubated with the secondary 
antibody for 1h at 4°C. Specific antibodies and their dilutions in the 2% BSA solution are 
listed in the table below (Table 5). Nuclear staining was performed by incubating the cells 
for 5 min at room temperature with DAPI. Cells were mounted on a microscope slide with 
VECTASHIELD Antifade Mounting Medium (Vector Laboratories, Burlingame, CA) to 
protect fluorophores from photobleaching. Images were taken with a scanning confocal 
microscope using a 63x objective with immersion oil. On seldom occasions, images were 
alternatively taken using an Axioskop 2 phase-contrast/epifluorescence microscope (Carl 
Zeiss, Thornwood, NY). 
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Table 5: Listing of antibodies used for IF and their dilutions 
Targeted against Tag Host Class Supplier Dilution 
HA epitope tag None Mouse Monoclonal Covance 1:500 
EEA1 None Mouse Polyclonal Santa Cruz 1:100 
Rab5 None Mouse Polyclonal  Santa Cruz 1:100 
Mouse Alexa Fluor 488 Goat Polyclonal Thermo Fisher 1:200 
Mouse Alexa Fluor 543 Goat Polyclonal Thermo Fisher 1:200 
 
2.7 Cell Surface Biotinylation 
Adherent cells transiently expressing eGFP-NHE6 were cultured in 12-well plates and grown 
to approximately 70% confluence on 15mm diameter glass coverslips (Thermo Fisher 
Scientific). The experiment was carried in duplicates for each cell line and experimental 
condition. Culture medium was replaced with fresh serum free medium and cells were left 
undisturbed for 2h prior to the hypoxic stimulation. Both PBS C/M (1mM CaCl2/0.5mM 
MgCl2) and a quenching solution (PBS C/M + 750mg Glycine) were freshly prepared and an 
aliquot of each of these solutions was placed in the hypoxic chamber for a total of 6h before 
use in order to equilibrate the O2 concentration. Half of the cells were placed into the hypoxic 
workstation for a duration of 4h. EZ-LinkTM Sulfo-NHS-SS-Biotin (Thermo Fisher 
Scientific) was dissolved into PBS C/M at a concentration of 0.3mg/ml immediately before 
use. After being washed three times with PBS C/M, the cells were covered with the biotin 
solution and incubated for 5 min with a gentle rocking motion. The biotin solution was 
removed and the cells were washed twice with the quenching solution to cleave any excess 
Biotin reagent that may not have yet reacted. Cells were then removed from the hypoxic 
workstation and immediately fixed for 10 min at room temperature in 1% PFA dissolved in 
PBS. Afterwards, cells were washed thoroughly with PBS and blocked for 1 h in 5% BSA 
dissolved in PBS (pH adjusted at 8.0). Streptavidin Texas Red conjugate (Thermo Fisher 
Scientific) diluted to 5μg/ml in the 5% BSA solution mentioned above was used to stain 
biotinylated cell-surface proteins (and other biomolecules containing primary amines) for 1h 
at 4°C. Coverslips were washed and mounted on microscope slides using VECTASHIELD 
Antifade Mounting Medium (Vector Laboratories). 
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The scanning confocal microscope was used with a 63X objective to take pictures of 15-20 
cells per experimental condition; pictures were taken at the depth representing the widest 
surface area for each cell. Duplicates were used only if one coverslip was unusable or broken. 
The cells systematically selected for data analysis were all of normal size (outliers were 
excluded), had even biotin staining at the cell-surface and had similar levels of eGFP-NHE6 
fluorescence intensity. The Fluoview software package was used for quantification of plasma 
membrane eGFP-NHE6. Intensity thresholds were set for both eGFP and Texas Red in order 
to remove any background or non-specific signal. These thresholds were kept constant for 
the analysis of all the series of pictures included in the experiment. For each cell, the 
percentage of cell membrane eGFP-NHE6 was calculated by performing a count of eGFP-
NHE6 positive pixels co-localized with the biotin labeled cell membrane and dividing with 
the total number of eGFP positive pixels. For each series, the average cell membrane 
percentage of eGFP-NHE6 was calculated.  
 
2.8 Complementary Confocal Microscopy Protocols 
Alexa-Fluor 546-conjugated transferrin (Thermo Fisher Scientific) was added to adherent 
cells at a concentration of 25μg/ml for 30 min prior to live cell visualization in order to mark 
early and recycling endosomes. This protocol was used either in conjugation with the HPTS 
probe or in cells expressing eGFP-NHE6. Similarly, cells were stained with lysotracker deep 
red (Thermo Fisher Scientific) for 30 min at 100nM to mark lysosomes.  CellROX Green 
Reagent (Thermo Fisher Scientific) was used as an indicator of reactive oxygen species 
(ROS). The fluorescent probe was added to adherent cells at a concentration of 5μM for 30 
min before being washed and brought to the confocal microscope for visualization. A 
40mWnm diode laser was used to excite the CellROX Green Reagent probe at 488nm. The 
fluorescent signal was collected around the emission maximum of 520nm. Light emission 
intensity, reflecting the extent of oxidative stress, was quantified in arbitrary units using the 
Fluoview software package. The average fluorescence intensity per cell was calculated; in 
order to stain the nuclei and differentiate between individual cells Hoechst 33342 was used 
(see above procedure). This technique was also applied in conjugation with the intracellular 
localization of doxorubicin protocol.  
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2.9 Western Blotting and co-Immunoprecipitation 
Cells were grown in 10 or 15cm petri dishes to a confluence of approximately 70%, serum 
starved for 2 h and lysed on ice with NP-40 lysis buffer (50 mM Tris-HCL pH 8.0, 150 mM 
NaCl, 1% NP-40, 5mM EDTA, phosphatase and protease inhibitors) after indicated 
stimulations (see Figure legends). Time-courses of hypoxic stimulations were performed 
using intermittent start times to allow simultaneous harvesting of the cells from all 
experimental conditions. Cell lysates were collected and mildly agitated for 30 min before 
being centrifuged at 13,000 RPM (30 min, 4°C) in order to recover sample supernatant. 
Protein concentration in each sample was determined using the colorimetric BCA reagent 
(Thermo Fisher Scientific) in accordance with manufacturer’s instructions. 
Samples prepared for co-IP were adjusted to equal protein concentrations in 500μl lysis 
buffer (ranging from 350 to 500μg depending on the experiment). Remaining total protein 
lysates were kept at 4°C to serve as inputs. Samples were pre-cleared for 45 min using protein 
G-agarose beads (Sigma Aldrich) and supernatants were collected. Protein lysates were 
conjugated with the corresponding antibody by incubating overnight at 4°C with mild 
agitation. Protein G-agarose beads were added to the lysates the following morning and 
allowed to bind antibodies for 3h at 4° with mild agitation. Following thorough washing with 
NP-40 buffer, the beads were suspended into 30μl of 4X Laemmli loading buffer (250mM 
Tris-HCl pH 6.8, 4% sodium dodecyl sulfate [SDS], 40% Glycerol, 0.05% bromophenol 
blue). Similarly, Laemmli loading buffer was added to inputs (20μg of proteins) in a 1:3 ratio 
to obtain a 1X concentration. β-mercaptoethanol was added separately to either sample at a 
concentration of 5%. Samples were incubated for 30 min at room temperature in Laemmli 
buffer; this variation of protein denaturation is done alternatively to boiling to avoid creating 
transmembrane protein aggregates. Separating gels of 10% acrylamide (40% Acrylamide: 
Bis-Acrylamide 35.5:1, Thermo Fisher Scientific) and stacking gels of 4% Acrylamide were 
freshly prepared. SDS polyacrylamide gel electrophoresis (PAGE) was used to separate 
proteins by migrating in a running buffer (0.1% SDS, 25mM Tris-Base and 192mM Glycine) 
for approximately 90 min at 110V. Proteins were subsequently transferred from the gel onto 
a polyvinylidene fluoride membrane (PVDF, Sigma Aldrich) using a wet transfer apparatus 
filled with transfer buffer (20% methanol, 25mM Tris-Base and 192mM glycine). PVDF 
membranes were washed for 20 min in Tris-buffered saline (TBS) and placed in a Blotto-
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Tween 20 blocking solution (5% non-fat carnation dry milk, 0.05% Tween 20 in a TBS 
solution) for 1h on a rotary plate. Membranes were then immunoblotted with the primary 
antibody overnight at 4°C on a rotary plate; antibody concentrations were optimized with 
manufacturer’s instructions.  Membranes were then submitted to appropriate wash steps and 
incubated for 3 h with horseradish peroxidase (HRP) conjugated secondary mouse or rabbit 
antibodies (Abcam) at a concentration of 1:10000. HRP chemiluminescence detection was 
performed using the Luminata Crescendo HRP substrate (EMD Millipore, Billerica, MA) as 
well as autoradiography hyperfilms.  
 
2.10 Multiple Sequence Alignment and Conservation Analysis 
Human Na+/H+ exchanger protein family was constructed from the 9 coding sequences from 
UniProt.org database corresponding to the longest isoform of each protein. The evolutionary 
relationship between these proteins was captured in a Newick tree format which was then 
used as input in phytools to visualize and customize the phylogenetic tree.  
Included in the multiple sequence alignment were the three human paralog sequences for 
NHE6, NHE7 and NHE9. Corresponding orthologs for two other mammalian species, the 
mouse and the giant panda, with highly homologous sequences, were also included in the 
bank of protein sequences. Additionally, seven more distantly related species (under 80% 
homology between NHE6 and homolog) were selected for the bank of protein sequences; 
considering the low number of sequenced NHE orthologs outside the clade of mammals, 
these species were selected on basis of availability on the UniProt.org database. Only 
orthologs including a cytoplasmic segment in their sequence were conserved for multiple 
sequence alignment (MSA). The number of identified paralogs eligible for analysis per 
species ranged from one to three; the entire dataset yielded twenty-five protein sequences. 
MSA was performed by entering UniProt identifiers into the Uniprot.org sequence alignment 
tool. The Jalview software was used to visualize the MSA output and to calculate amino acid 
residue conservation scores. Conservation index calculation is based on the Analysis of 
Multiply Aligned Sequences (AMAS) method of MSA (Livingstone, 1993) and measures the 
conservation of physico-chemical properties of amino acid residues. 
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2.11 Protein Disorder Propensity Analysis 
We explored four possible prediction methods for protein disorder propensity. The first of 
these is Meta-Disorder predictor (MD_raw) which is a neural-network based predictor that 
uses multiple independent sources of information to make predictions. The second predictor 
explored was the NORSnet method which is also based on neural network and focuses on 
distinguishing between long segments with non-regular secondary structures and well-folded 
proteins. The next prediction tool examined was the Ucon method which combines protein 
internal contacts with pairwise energy potentials to predict long unstructured regions. Lastly, 
we also looked at the PROFbval method which predicts the flexibility or rigidity of residues 
based on protein sequence. For our application, in which we aimed to reveal disorder 
differences on a micro level, we found that the MD_raw and Ucon methods provided the 
most sensitivity. These two methods also correlated closely with one another and were thus 
the two methods of choice used for our study. The standardized disorder scores were 
calculated by converting the lowest score for any individual residue within the protein to 0, 
the highest score to 1 and by grading any other scores obtained along that scale. This 
approach allowed comparing directly the scores obtained through either method. 
 
2.12 3D Molecular Visualization 
The PDB file named 4AOW for human RACK1 was obtained on the Research Collaboratory 
for Structural Bioinformatics (RCSB) protein data bank (PDB) website. The reported protein 
structure (Ruiz Carrillo, 2012) corresponds to crystals of three molecules and is available at 
a resolution of 2.45Å. PDB files were viewed using PyMOL 3D molecular visualization 
system.  
 
2.13 3D Peptide Folding and Molecular Docking Refinement Protocol 
PEP-FOLD 2.0 (Shen et al, 2014), a tool for de novo peptide structure prediction, was used 
to generate likely 3D peptide structures from original 10 aa FASTA sequences corresponding 
to NHE6 regions of interest. From the 10 peptides generated with each sequence, only the 
first model was used as an initial conformation for the subsequent molecular docking 
refinement protocol. 
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Input models for molecular docking protocols were prepared using PyMol viewer. Previously 
generated peptides were manually placed in the vicinity of predicted sites at the surface of 
RACK1. Those positions were saved into PDB files containing coordinates of the two 
molecules and submitted to the FlexPepDock protocol (Raveh et al, 2010), designed for high 
resolution modeling of peptide-protein interactions. The FlexPepDock protocol yielded 200 
possible structures (combinations of positions and conformations) obtained by trial and error 
for each peptide. This protocol obeys the Rosetta method and uses a Monte Carlo algorithm 
for conformational energy minimization. With each structure was calculated an interface 
energy score (I_sc), which is an indication of the stability of the complex formed. I_sc is 
expressed in Rosetta energy units. For each peptide, the structure with the lowest I_sc, which 
represents the most energetically favourable interaction, was selected and conserved for data 
analysis.  
 
2.14 Statistical Analysis 
Two-tailed paired or unpaired Student’s t-test were used to determine statistical differences 
between groups of data. The confidence level for statistical difference was set at 95% with 
*: p≤0.05, **: p≤0.01, ***: p≤0.001. Linear correlation of data was performed to determine 
the Pearson r coefficient; the confidence interval was set at 95%.  
 3. RESULTS  
Adherent HT1080 fibrosarcoma cells were used as the primary model in studying the 
interaction between NHE6 and RACK1 proteins. This cell line offered the handling 
advantages of dividing fairly rapidly and they can be easily transfected. This hypoxia 
responsive cell line was thus a convenient model to establish proof-of-concept and to 
investigate a novel mechanism involved in pH-dependent chemoresistance. Additionally, 
MDA-MB-231 mammary gland adenocarcinoma cells were used to confirm results from 
some of the key experiments. MDA-MB-231 were a more challenging cell line to handle due 
to slower division and to being a less-efficient transfection host; however, this cell line serves 
as a model for breast adenocarcinoma for which anthracyclines are commonly used as first 
line treatment in the clinic. 
The results falling under objective #1 and its sub-objectives are covered in sub-sections 3.1 
to 3.5 whereas the results falling under objective #2 are covered in sub-sections 3.6 to 3.9. 
 
3.1 Exposition to Hypoxia Induces Formation of a Complex Between Transiently 
Expressed NHE6 and RACK1. 
Co-immunoprecipitation assays were used to determine whether hypoxia affects the 
formation of a complex between transiently expressed NHE6 and the native RACK1 protein. 
HT1080 cells were transiently transfected with pcDNA3-HA or pcDNA3-HA/NHE6 and 
either kept in normoxia or placed under hypoxic condition for the indicated amount of time. 
NHE6-HA was immunoprecipatated with an anti-HA mouse monoclonal antibody. Levels of 
α-tubulin and of RACK1 in total lysates were fairly consistent among samples (Figure 5A). 
Expression of NHE6-HA was also consistent and immunoprecipitation of the protein was 
even across the four samples. The intensity of the RACK1 band in NHE6 immunoprecipitates 
was barely detectable for cell samples incubated at 21% O2, but increased with longer 
incubation times at 1% O2 (Figure 5A). Immunoprecipitated RACK1 bands were quantified 
and shown to increase by 16 folds for cells kept 4h in hypoxia compared to cells kept in 
normoxia (Figure 5B). A separate but similar experiment was performed where a 30 min 
incubation time at 1% O2 was included (Figure 5C).  
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Figure 5. Co-Immunoprecipitation of RACK1 with Transiently Expressed NHE6-HA 
in Cells Subjected to Hypoxia 
A) HT1080 cells were incubated at 21% O2 or 1% O2 for the indicated period of time. Total 
cell extracts were collected following cell lysis whereas the remaining cell lysates were 
incubated with mouse anti-HA monoclonal antibodies and protein G-agarose beads. An anti-
RACK1 rabbit monoclonal antibody was used to reveal RACK1. The first lane corresponds 
to experimental control samples where ev describes HT1080 cells transfected with pcDNA3-
HA empty vector. The remaining lanes represent HT1080 cells transiently expressing NHE6-
HA. Transient transfections were performed 24h ahead of the first incubation times. B) 
Quantification of RACK1, shown in A, that co-precipitate with NHE6. The slight band for 
the cells incubated at 21% O2 was set to a default value of 1. The bands corresponding to 
cells incubated at 1% O2 were expressed in fold change. C) Same general procedure as in A 
with the exception that an anti-RACK1 mouse monoclonal antibody was used. 
  
Endogenous RACK1 levels as well as expression of NHE6-HA in total cell extracts were 
relatively constant across all experimental conditions. NHE6-HA was fairly well 
immunoprecipitated in all samples, but the presence of co-immunoprecipitated RACK1 was 
clearly more elevated in cells incubated in hypoxia for 1h and 2h. In this particular 
experiment, the amount of RACK1 in complex with NHE6 clearly diminished at the longer 
incubation time of 4h. Two additional experiments (not shown) also displayed an increase in 
co-immunoprecipitated RACK1 in cells exposed to hypoxia with peak amounts of RACK1 
observed during the 1 to 4h incubation period. The kinetics of co-precipitated RACK1 were 
too variable to gain any additional insight from combining the results in a single 
densitometry.  
 
3.2 Cellular Expression of a Peptide Derived from the SLC9A6 Gene. 
The portion of the SLC9A6 gene corresponding to NHE6527-588 was isolated and amplified 
from peGFP-N3-NHE6 and then inserted upstream from the HA-tag coding sequence of the 
pcDNA3-HA vector. A positive clone obtained through sub-cloning was sequenced at the 
Génome Québec Innovation Centre (McGill University) to insure accuracy of the cloning 
and identity of the cloned sequence. Expression of the HA-tagged peptide was initially 
validated in HT1080 cells (Figure 6) and MDA-MB-231 cells (results not shown) by 
immunofluorescence using an anti-HA mouse monoclonal antibody. Negative controls were 
performed using cells transfected with pcDNA3 and no fluorescent signal was detected in 
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those samples (data not shown). A strong speckled pattern of fluorescence was revealed in 
cells overexpressing the NHE6527-588 peptide (Figure 6). We failed to detect the NHE6527-588 
peptide by immunoblotting presumably due to its small size (predicted to be 7KDa).  
 
 
 
Figure 6. Immunofluorescence image of the NHE6527-588 peptide 
The HA-tagged NHE6527-588 peptide was transiently expressed in HT1080 cells. Anti-HA 
mouse monoclonal antibody was used to detect the peptide in fixed cells. Cells were then 
stained with anti-mouse Alexa-fluor 488 antibody and observed under a Zeiss Axioskop 2 
phase-contrast/epifluorescence microscope. 
 
3.3 Assessment of the Functional Effects from Expression of the NHE6527-588 Peptide. 
3.3.1 Expression of the NHE6527-588 Peptide Prevents Formation of an Hypoxia-Inducible 
Complex between Transiently Expressed NHE6 and Endogenous RACK1. 
Co-immunoprecipitation experiments were performed in order to determine whether the 
expression of the NHE6527-588 peptide affects hypoxia-induced formation of a complex 
between NHE6 and RACK1. The peGFP-N3-NHE6 vector was transiently transfected into 
either parental MDA-MB-231 cells or MDA-MB-231 cells stably expressing the NHE6527-
588 peptide. No control lacking transfected peGFP-N3-NHE6 vector was included in this 
particular experiment. For the parental cell line, either pcDNA3-HA or pcDNA3-
HA/NHE6527-588 was transiently transfected alongside peGFP-N3-NHE6. NHE6-GFP was 
immunoprecipitated with an anti-GFP rabbit polyclonal antibody. Total protein extracts 
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yielded similar levels of RACK1 and NHE6-GFP across all 4 samples (Figure 7). Despite 
seemingly less effective NHE6 immunoprecipitation, the sample from control cells (ev) 
exposed to hypoxia for 4h, clearly yielded the highest amounts of RACK1 proteins in the 
NHE6 immunoprecipitate. In comparison, a smaller amount of RACK1 (-0.65 fold change) 
was detected in the NHE6 immunoprecipitate from cells transiently expressing the NHE6527-
588 peptide whereas the sample stably expressing NHE6527-588 peptide yielded no visible 
RACK1. Similar results were obtained with HT1080 cells overexpressing the NHE6527-588 
peptide (data not shown). We concluded that the NHE6527-588 peptide indeed acted as an 
inhibitor of NHE6/RACK1 complex formation and that stable expression of this peptide was 
more effective than its transient expression. Subsequent experiments were thus performed 
using the stably expressing NHE6527-588 MDA-MB-231 cell line. 
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Figure 7. Co-Immunoprecipitation of RACK1 and NHE6-GFP in MDA-MB-231 cells 
overexpressing the NHE6527-588 peptide. 
Parental MDA-MB-231 (control cells) or MDA-MB-231 cells stably expressing pcDNA3-
HA with encoded NHE6527-588 peptide were transiently transfected with peGFP-N3-NHE6. 
Additionally, control cells were co-transected with pcDNA3-HA or pcDNA3-HA/NHE6527-
588. Transient transfections were performed 48h prior to incubation at 21% O2 or 1% O2  for 
4h as previously described. Cell lysates were incubated with rabbit anti-GFP polyclonal 
antibodies and protein A-agarose beads.  An anti-RACK1 mouse monoclonal antibody was 
used to reveal RACK1. 
 
 
3.3.2 Hypoxia Favors NHE6 Plasmalemmal Localization in Human Cancer Cell Lines; 
this Trend is Countered by Expression of the NHE6527-588 Peptide. 
A cell-surface biotinylation protocol was adapted to allow simultaneous visualization of 
eGFP-NHE6 and its quantification at the plasma membrane. For this purpose, sulfo-NHS-
SS-Biotin with Streptavidin Texas Red conjugate were used to stain cell-surface proteins. 
HT1080 cells incubated under hypoxia for 4h showed a distinct change in the pattern of 
eGFP-NHE6 distribution with an increased overlap between the eGFP-NHE6 and the cell-
surface biotin signals (Figure 8A). The proportion of eGFP-NHE6 overlapping with the 
plasma membrane was shown to be significantly higher in cells incubated in hypoxia 
(HT1080, p=0.0063; MDA-MB-231, p=0.0019) (Figure 8B). Similar results were observed 
in HT1080 cells although plasmalemmal levels were comparatively higher in these cells. 
Stable expression of the NHE6527-588 peptide prevented the increased plasmalemmal 
localization of eGFP-NHE6 in HT1080 cells incubated for 4h in hypoxia (NHE6527-588), 
p=0.6637) (Figure 8C). 
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Figure 8. Subcellular localization of NHE6 in hypoxia. 
A) Representative images of transiently expressed eGFP-NHE6 in HT1080 cells incubated 
under normoxic and hypoxic conditions. Sulfo-NHS-SS-Biotin in conjugation with 
Streptavidin Texas Red conjugate were used to stain cell-surface proteins (including glyco-
proteins) thus acting as a proxy for the cell membrane. Cells were kept in hypoxia (1% O2) 
for 4h. B) The percentage of eGFP-NHE6 present at the plasma membrane was quantitated 
in both HT1080 and MDA-MB-231 cells by using the overlapping signal from Biotin. C) 
The percentage of eGFP-NHE6 at the plasma membrane was similarly quantitated in stably 
expressing NHE6(527-588) HT1080 cells (or empty vector expressing cells). The asterisks used 
to indicate statistical differences correspond to: * p<0.05, ** p<0.01 and *** p<0.001. 
 
 
3.3.3 The Acidification of the Endosomal/Lysosomal pH in Cells Exposed to Hypoxic 
Conditions is Attenuated by Expression of the NHE6527-588 Peptide. 
As previously reported (Lucien et al., 2014), incubation of live cells with HPTS has the result 
of incorporating the probe into endosomes and lysosomes, which allows subsequent 
ratiometric measurements of the pH in these cell compartments. The adequate localization of 
the probe was validated for both HT1080 and MDA-MB0231 cells by co-incubating the cells 
with transferrin and lysotracker, respectively used to label endosomes and lysosomes, 
respectively. HPTS was shown to localize in similar proportions in endosomes and 
lysosomes in HT1080 cells (Figure 9A) whereas it primarily localized in endosomes in 
MDA-MB-231 cells. In both cases, HPTS was predominantly localized in either endosomes 
or lysosomes with only 8.7% and 8.0% of the probe respectively excluded from either 
compartment. Different incubation times in hypoxia were performed and revealed that both 
the endosomal and lysosomal compartments were effectively acidified in HT1080 cells at the  
3h and 4h time points (3h, p=0.0111; 4h, p=0.0015) (Figure 9B). The sharpest decrease in 
pH was observed in cells incubated 4h in hypoxia, with values ranging from 6.6 in normoxia 
to 5.8; longer incubation times in hypoxia yielded similar results to the 4h time point (not 
shown). Endosomal/lysosomal acidification in hypoxia was also observed in MDA-MB-231 
cells at the 4h time point (Figure 9C). Expression of the NHE6527-588 peptide in cells 
prevented or attenuated acidification of the endosomal/lysosomal compartments in both 
HT1080 and MDA-MB-231 cell lines (HT1080 NHE6527-588), p=0.5286; MDA-MB-231 
NHE6527-588); p=0.5693).  
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Figure 9. Measurement of endosomal/lysosomal pH in living cells.  
A) Visualization of HPTS incorporated in live HT1080 cells at both fluorescence excitation 
maxima (405nm and 458nm). Cells were simultaneously incubated with transferrin and 
lysotracker in order to label endosomes and lysosomes, respectively. The signals used for 
identifying sub-cellular compartments were merged with images collected from excitation 
at 405nm (which produced the sharper signal). Merged images were used to calculate the 
percentage of HPTS present in each sub-cellular compartment. The same procedure was 
followed for MDA-MB-231 cells. B) HT1080 cells pre-incubated with HPTS were 
incubated under normoxia or hypoxia (1% O2) for the indicated times. Live cells were 
excited at 458nm and 405 nm and HPTS fluorescence intensity was collected. The resulting 
458/405nm ratios were converted to pH values using pre-made pH calibration curves. C) 
pH measurements were performed in stably expressing NHE6(527-588) HT1080 and MDA-
MB-231 cells (or equivalent empty vector cells) as indicated in B. Cells were incubated in 
hypoxia for 4h. The asterisks used to indicate statistical differences correspond to: 
* p<0.05, ** p<0.01 and *** p<0.001. 
 
 
3.3.4 Localization of Doxorubicin in the Nucleus is Diminished in Hypoxia; Expression 
of NHE6527-588 Peptide Restores the Nuclear Levels of Doxorubicin.  
The experimental design showing subcellular distribution of doxorubicin in HT1080 cells 
presented in the preliminary findings was replicated using cells stably expressing NHE6527-  
588. Although spots of extra nuclear doxorubicin in hypoxia were not as clearly defined in 
empty vector expressing cells (Figure10A) as in our earlier experiments, the trend showed 
less nuclear doxorubicin in cells incubated in hypoxia (empty vector, p=0.0047) 
(Figure10B). Conversely, the cellular distribution of doxorubicin was not visibly altered by 
hypoxia (Figure10A), an observation that was confirmed by the quantification of nuclear 
doxorubicin (NHE6527-588, p=0.6088) (Figure10B). 
 
 
 
57 
 
Figure 10. Subcellular distribution of doxorubicin in stably expressing NHE6 (527-588) 
HT1080 cells. 
A) Representative images of sub-cellular distribution of doxorubicin in live HT1080 cells, 
stably expressing the NHE6(527-588) peptide or the control empty vector and incubated under 
normoxic or hypoxic conditions for 4 h. The nucleus was stained by incubating cells with 
Hoechst 33342. B) The percentage of doxorubicin present at the nucleus was quantitated 
using the overlapping signal from Hoechst 33342. The asterisks used to indicate statistical 
differences correspond to: * p<0.05, ** p<0.01 and *** p<0.001. 
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3.4 Activation of PKC Produces Effects Similar to Hypoxia on NHE6 Localization, 
Endosomal/Lysosomal pH Modulation and Doxorubicin Distribution. 
Phorbol 12,13-dibutyrate (PDBU), an activator of classical and novel PKC isozymes, was 
used to assess the implication of PKC signaling in pH-associated chemoresistance. HT1080 
cells transiently expressing eGFP-NHE6 and treated for 2h with 100nM PDBU revealed a 
clear change in the distribution of NHE6 (Figure 11A). EGFP-NHE6 in PDBU-treated cells 
appeared more abundantly located at the plasma membrane in both experiments. The 
proportion of eGFP-NHE6 at the plasma membrane was however not quantitated. Parallel 
pH measurements indicated a much lower endosomal/lysosomal pH of 4.82 in cells subjected 
to 100nM PDBU as opposed to a pH of 6.00 in untreated cells (Figure 11B). This experiment 
was only performed once and could not be validated for statistical significance. Visualization 
of live HT1080 cells pre-incubated for 2h with 100nM PDBU before addition of doxorubicin 
revealed an increase in extra-nuclear spots of the drug (Figure 11C). A tendency towards 
less nuclear doxorubicin for HT1080 cells treated with PDBU was revealed (PDBU 100nM 
compared to untreated, p=0.0493) (Figure 11D). Another sample of HT1080 cells was 
treated in parallel with 200nM of GF109203X for 30 min prior to being incubated in hypoxia 
for 4h and incubated with doxorubicin as mentioned above. GF109203X at concentrations 
under 1μM is used as a selective inhibitor of PKC isozymes activation (Toullec et al, 1991). 
Pre-treatment with GF109203X (GF) seems to have prevented the endosomal/lysosomal 
acidification as observed in untreated hypoxic cells; statistical significance could not, 
however, be attained within three duplicates of the experiment (GF 200nM, p=0.1234) 
(Figure 11D). 
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Figure 11. Effect of PKC activity modulation on NHE6 localisation, 
endosomal/lysosomal pH and doxorubicin distribution. 
A) Representative images of transiently expressed eGFP-NHE6 in untreated HT1080 cells 
or cells treated with 100nM PDBU for 2h. The nuclei were stained by incubating cells with 
DAPI. B) Endosomal/lysosomal pH measurements were performed in live HT1080 cells and 
MDA-MB-231 cells as indicated in Figure 10B. HT1080 cells were treated with 100nM 
PDBU for 2h prior to visualization. C) Representative images of sub-cellular distribution of 
doxorubicin in live HT1080 cells incubated for 2h with PDBU or control cells. Nuclei were 
stained with Hoechst 33342. D) The percentage of doxorubicin present at the nucleus was 
quantitated by using the overlapping signal from Hoechst 33342.  
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3.5 Reactive Oxygen Species Produced in Hypoxia Correlate Positively with Extra-
Nuclear Distribution of Doxorubicin. 
 
Hypoxia is known as a common stimulus for the generation of mitochondrial reactive 
oxygen species (ROS) and for ROS produced through NADPH oxidases (Klimova and 
Chandel, 2008). ROS are also among the molecules known to trigger the switch between 
the inactive and the active conformations of PKC isozymes. We first validated the capacity 
of hypoxia to stimulation of ROS production in our HT1080 experimental cell model. For 
this, total ROS were stained using CellROX Green indicator. Results showed an increase in 
ROS production (4.8 fold, p=0.0328) in hypoxic over normoxic cells (Figure 12A). In 
order to investigate whether there is a link between total ROS and pH-dependent 
chemoresistance, the simultaneous staining of ROS and nuclei were performed on live 
HT1080 cells following incubation with doxorubicin. The results revealed that the amounts 
or ROS are variable from cell to cell within each culture (Figure 12B). Notably, cells 
exhibiting higher levels of ROS have more extra-nuclear spots of doxorubicin (left circle) 
than cells with lower levels of ROS (right circle). CellROX Green signal intensity levels 
were quantitated and correlated for each individual cell with the proportion of nuclear 
doxorubicin (Figure 12C). For each of the three experiments carried out, a statistically 
significant negative correlation was found between the percentage of nuclear doxorubicin 
and the amount of total ROS in cells or surrounding the cells. Further statistical details 
describing the linear correlation relationships are provided in Figure 12C. 
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Figure 12. ROS production in hypoxia and correlation with doxorubicin distribution 
in live HT1080 cells. 
A) Representative images of CellROX Green indicator of reactive oxygen species in live 
HT1080 cells incubated under normoxia or hypoxia for 4h. The nuclei were stained by 
incubating cells with Hoechst 33342. CellROX green signal was collected around the 
emission maxima of 520nm. Signal intensity is expressed in fold based on a value of 1 for 
cells kept under normoxia. B) Field of live HT1080 cells placed 4h under hypoxia and 
incubated during that time in succession with doxorubicin for 2h and with CellROX Green 
reagent for 30 min. Cells contained in the field display varying doxorubicin distribution and 
varying degrees of ROS. The cell shown in the left circle has a low percentage of nuclear 
doxorubicin and high level of ROS. The cell shown in the right circle has a high percentage 
of nuclear doxorubicin and low levels of ROS. C) Experimental conditions described in B 
were repeated on three occasions. Nuclear doxorubicin and CellROX Green were calculated 
for individual cells and data were used to determine the Pearson r correlation coefficient and 
the coefficient of determination. The asterisks used to indicate statistical differences 
correspond to: * p<0.05, ** p<0.01 and *** p<0.001. 
 
 
3.6 Multiple Sequence Alignment of Human NHE6, 7 & 9 with Orthologs from Other 
Species Reveal a Strongly Conserved Sequence within the RACK1 Binding 
Domain.  
The DNA coding sequences of the nine human Na+/H+ exchangers were aligned to construct 
a phylogenetic tree of the NHE protein family and to reveal similarities and differences 
between members of the family (Figure 13). As expected, the plasma membrane exchangers 
formed a sub-family of five closely related proteins members. Within that sub-family NHE1, 
2 and 4 were all within a short evolutionary distance; these three exchangers are the only 
members of the family to contain a calmodulin binding domain. The four remaining members 
of the protein family are all intracellular exchangers and three of those, NHE6, 7 and 9, form 
a closely related subset. A RACK1 binding domain has been identified for these three 
members of the NHE family whereas human NHE8 does not contain such domain. 
 
 
63 
 
Figure 13. Phylogenetic tree of human NHE proteins divided into subfamilies 
Phylogenetic tree constructed using the sequences of the nine human NHE paralogs (longest 
isoforms). Evolutionary distance shown on the x axis is expressed accordingly to the 
proportion of nucleotide substitution. The first five exchangers shown at the top constitute a 
subfamily defined by their plasmalemmal subcellular localization. This subfamily can be 
further divided into proteins containing calmodulin binding domains (blue branches) and 
those that do not contain such domains. The last four exchangers shown at the bottom 
constitute a subfamily defined by their intracellular localization. This subfamily can equally 
be further divided into proteins containing a RACK1 binding domain (red branches) and 
those that do not contain such domain. 
 
A total of twenty-five protein sequences arising from NHE6, NHE7, NHE9 and 
corresponding orthologs from 9 species other than human were selected for multiple 
sequence alignment. The twenty-five genes selected as well as the corresponding species are 
listed in table 6. Also indicated is the % homology between human NHE6 and its orthologous 
gene found in different species. 
 
MSA of the twenty-five proteins reveals regions of residue conservation for the entire set of 
sequences. The 12 known transmembrane domains as well as the RACK1 binding domain of 
human NHE6 were aligned underneath the map of residue conservation to better delineate 
areas of high conservation and areas of low conservation (Figure 14A). The twelve 
transmembrane domains have a tendency to situate themselves within the boundaries of 
either regions of high conservation (deep blue) or of medium conservation (light blue), they 
seldom crossover areas of low conservation (white). A close-up of the map corresponding to 
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the cytoplasmic tail reveals that the region of interaction with RACK1 is contained within 
the largest and most conserved portion of cytoplasmic component of this NHE protein subset 
(Figure 14B). Further zooming on the RACK1 region of interaction shows the conservation 
index for each individual residue (Figure 14C). Within this well-conserved region, it is 
possible to further isolate a portion of the most well-conserved 28 amino acids within the 
cytoplasmic tail. For human NHE6 variant B this sequence would start at F-536 and end at 
P-563.  
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Table 6: Intracellular NHE sequences included in the dataset used for MSA. 
Species 
(common name, uniprot 
taxon identifier and 
binomial nomenclature) 
Paralogs 
(human 
equivalent) 
Uniprot Identifiers 
% homology 
(NHE6 homolog 
with human 
NHE6) 
Human, 9606,               
Homo sapiens 
NHE6, 7 & 9 Q92581, Q96T83, 
Q8IVB4, 
100 
Mouse, 10090,                 
Mus musculus,  
NHE6, 7 & 9 A1L3P4, Q8BLV3, 
Q8BZ00 
96 
Panda géant, 9646, 
Ailuropoda melanoleuca 
NHE6, 7 & 9 G1L8J1, D2HXE1, 
G1M2B1 
92 
Green anole (lizard), 28377, 
Anolis Carolinensis 
NHE6 & 9 H9GJ49, G1KJ91 79 
Chicken, 9031,             
Gallus gallus 
NHE6, 7 & 9 F1NCB2, F1NEV4, 
F1NYM1 
79 
Zebra finch, 59729, 
Taeniopygia guttata 
NHE6, 7 & 9 H0YXF3, H0ZK15, 
H0ZEK3 
78 
Frog, 8364,               
Xenopus silunanra tropicalis 
NHE6 & 7 F6PUK5, F7BFD2 77 
Turtle, 13735,        
Pelodiscus sinensis 
NHE6, 7 & 9 K7FR39, K7FV38, 
K7GDV6 
75 
Spotted gar (fish), 7918, 
Lepisosteus oculatus 
NHE6 & 7 W5ND83, W5MNB8 72 
Blind cave fish, 7994, 
Astyanax mexicanus 
NHE6 W5KM86 57 
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Figure 14. MSA analysis of a subfamily of intracellular Na+/H+ exchangers. 
A) MSA of the twenty-five protein dataset listed in table 6 aligned with the principal domains 
of the human NHE6 protein. Deep blue areas indicate regions of high conservation, light blue 
areas indicate regions of medium conservation and white areas indicate regions of low 
conservation. Tall yellow bars shown beneath also indicate regions of high conservation and 
are based on the conservation index calculated with the AMAS method. Although no protein 
has a total length of 727 amino acids, the 1st residue is aligned with the protein with the 
longest N-terminal segment and the 727th residue is aligned with the protein with the longest 
C-terminal segment.  B) Close-up of the cytoplasmic tail containing the region of interaction 
with RACK1 is highlighted in purple.  C) Close-up of the region of interaction with RACK1. 
The conservation index shown at the bottom is calculated on a scale of 1 to 10, with score of 
10 indicated by *. A red box is used to highlight a sequence of 28aa that is the most conserved 
within this region. 
 
 
3.7 Analysis of NHE6 RACK1 Binding Domain as a Segment Involved in Inducible 
Transient Protein-Protein Interactions. 
Results obtained thus far through co-immunoprecipitation and protein-protein interaction 
behaviour of similar WD40 repeat proteins (Chen et al, 2004) lead us to believe that the 
NHE6 RACK1 interaction fits the description of a strong inducible transient protein-protein 
interaction. This section will seek to analyze the biochemical properties of NHE6 residues at 
or near the interaction interface and compare those findings to common characteristics for 
transient interactions.  
 
3.7.1 A Segment of the Human NHE6 RACK1 Binding Domain is Enriched in Neutral 
Polar Residues. 
Transient interfaces tend to be quite compact and smaller in size than permanent interfaces 
(Perkins, 2010). These interfaces are also enriched in neutral polar residues; this observation 
is somewhat intuitive considering that these protein segments need to be soluble to allow 
interacting proteins to dissociate as is the nature of transient protein-protein interactions. Six 
of the twenty standard amino acids fall under the category of neutral polar residues (Figure 
15A), these include Serine (S), Threonine (T), Cysteine (C), Tyrosine (Y), Asparagine (N) 
and Glutamine (Q). A segment of thirty-three amino acids enriched in neutral polar residues 
could be identified within the RACK1 binding domain of NHE6 (Figure 16B). This segment 
is composed at 45.5% of neutral polar residues whereas the entire cytoplasmic tail of human 
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NHE6 is only composed at 27.5% of neutral polar residues. The thirty-three amino acid 
segment stretches from T-551 to Q-583.  
  
Figure 15. Neutral polar residue enrichment in transient interfaces. 
A) Representation of the six standard amino acids sharing the characteristic of neutral polar 
residues.  B)  Annotated sequence of the NHE6 [527-588] RACK1 interaction region 
showing neutral polar residues in green. The green box indicates the segment most enriched 
in neutral polar amino acids.  
 
 
3.7.2 The Human NHE6 RACK1 Binding Domain has Characteristics of an Intrinsically 
Disordered C-terminal Region and Contains Several Possible Anchoring Residues. 
Another feature of transient protein interactions is that they tend to occur within intrinsically 
disordered (ID) proteins (Perkins et al, 2010). ID can best be described as proteins or protein 
segments, that lack a specific structure; or in other words that can adopt a wide range of 
conformations. The distal part of the NHE1 C-terminal tail has previously been shown to be 
ID and was proposed to contain molecular recognition features (MORFs) necessary for 
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proper NHE1 trafficking to the plasma membrane (Nørholm et al, 2011) Protein disorder 
propensity analysis based on the UCON and MD_Raw methods were applied to the 
cytoplasmic C-terminal segment of NHE6.  The scores obtained through the two methods 
were well correlated with each other and showed that the cytoplasmic C-terminal segment of 
NHE6 is generally disordered (Figure 16A). As the characteristics of transitory protein-
protein interactions remain poorly defined in the literature, we examined the molecular 
details of the p53 interactions with MDM2 and Taz2 proteins (Huang and Liu, 2011) as a 
comparison model for the NHE6 and RACK1 interaction. These interactions are some of the 
few transient interactions for which precise molecular regulation has been described and 
involve anchorage residues necessary to create the protein interface. The same methods were 
thus also applied to the first 40 amino acids of human P53 (Figure 16B), which are contained 
in the P53 transactivation domain. Similarly, this segment of P53 was generally disordered. 
In both cases protein residue disorder was examined in more details where it was observed 
that a segment of 33 amino acids, ranging from A-529 to L-561, was below the threshold for 
disordered nucleotide residues (Figure 16C). Likewise, the P53 segment contained 6 amino 
acids, all within F-19 and L-26, which were also below the threshold for disordered 
nucleotide residues. Three of these residues, F-19, W-23 and L-26, correspond to the three 
residues that have been identified as anchorage residues involved in the transient interaction 
with MDM2 (Huang and Liu, 2011) (Figure 16D). Highlighted in purple within the NHE6 
sequence are the Arginine (R), Tyrosine (Y), Phenylalanine (F) and Tryptophan (W) amino 
acids which are known to often serve the function of anchorage residues. It must be noted 
that theses residues are concentrated in the region ranging from W-533 to Y-545 which 
corresponds to the most intrinsically disordered region of the NHE6 cytoplasmic C-terminal 
segment. 
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Figure 16. Protein segment disorder propensity predicted using two alternative 
methods. 
A) Standardized UCON and MD_raw disorder scores of the NHE6 cytoplasmic segment, the 
RACK1 interaction sequence [527-588] is shown within brackets. B) Standardized UCON 
and MD_raw disorder scores of the P53 N terminal segment. C) Annotated sequences from 
A (only RACK1 interaction sequence) and B. Ordered residues shown in black correspond 
to UCON scores of x < 0.1, intermediate sequences shown in blue correspond to UCON 
scores of 0.1 ≤ x < 0.25 and disordered sequences correspond to UCON scores of x ≥ 0.25. 
D) Annotated sequences showing residues of the NHE6 cytoplasmic segment suspected of 
acting as anchorage residues (purple) binding to a RACK1 surface cavity and the previously 
confirmed anchor residues on the P53 N-terminal segment which are involved in the 
interaction of p53 to a surface cavity of MDM2.  
 
 
3.8 Overlapping Residues Forming a Cavity at the Surface of RACK1 and Possibly 
Involved in the Interaction with NHE6 were Identified Through Two Alternative 
Methods. 
Since the human NHE6-RACK1 binding domain contains several well-conserved proline 
residues within its core, we investigated the possibility that NHE6 binds RACK1 in a similar 
type of protein-protein interaction as described for proline-rich motifs (PRMs). PRM 
recognition has been shown to involve clusters of exposed aromatic residues called “aromatic 
cradles” (Ball et al, 2005). Systematic inspection of the crystal structure of human RACK1 
(PDB file: 4AOW), revealed two clusters of exposed aromatic residues at the surface of 
RACK1. One of these sites was found within the WD2 domain on the top face (arbitrarily 
determined) of RACK1; as shown in Figure 17A, it involves a histidine residue (H), a 
phenylalanine residue (F) and a tryptophan residue (W). The second site was found located 
between the WD4 and WD5 and involves two tryptophan residues (W) and one tyrosine 
residue (Y). A third site that involves four residues of the WD6 domain was also found on 
the bottom face of RACK1 (Figure 17B); this site involves two tyrosine (Y) residues, one 
phenylalanine residue (F) and one tryptophan (W) residue. Alternatively, the IsoCleft Finder 
tool (Kurbatova, 2013) was used to detect cavities at the surface of RACK1 that were 
projected to be involved in molecular interactions based on similarities found in an existing 
database of proteins with known molecular interactions. Only one site was identified through 
this method in domains WD5-7 that can correspond to the typical small size of transient 
protein-protein interactions (Figure 17C). This cavity is formed by a total of 12 residues 
 
 
72 
found on the WD5 and WD6 domains of the bottom face of the human RACK1 protein. The 
two sites identified on the bottom face of RACK1 partially overlapped with the two tyrosine 
residues found on both sites; the remaining residues were adjacent to each other. This 
possible binding site will simply be referred to as tentative NHE binding pocket moving 
forward. 
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Figure 17. Identification of potential protein binding sites at the surface of RACK1. 
A) View of the top face of the RACK1 protein and amino acid sequence of the 7 WD repeat 
domains. The first site corresponding to the description of an aromatic cradle (blue) involves 
three aromatic residues (HFW) of the WD2 domain. The second site corresponding to the 
description of an aromatic cradle (orange) involves two tryptophan residues of WD4 domain 
and one tyrosine residue of the WD5 domain. B) View of the bottom face of the RACK1 
protein. The third site corresponding to the description of an aromatic cradle (red) involves 
four aromatic residues (YFYW) of the WD6 domain.  C)  View of the bottom face of the 
RACK1 protein. The possible interaction site identified through IsoCleft Finder (violet) 
involves twelve residues contained in the WD5 and WD6 domains. Images captured with 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
 
3.9 NHE6 Segment Rich in Potential Anchorage Residues around Y-539 is Predicted 
to be Involved in Forming an Energetically Favourable Complex with RACK1. 
A peptide-protein molecular docking refinement protocol was used as a tool to help further 
refining key residues in the NHE6 RACK1 binding domain. To do so, the [527-588] NHE6 
sequence of 62 amino acids was separated into eleven arbitrarily generated 10 amino acid 
overlapping peptides and each one was assigned a letter as shown in Figure 18A. We then 
generated a 3D structure with the most likely initial conformation for every peptide using the 
PEP-FOLD de novo peptide structure prediction tool. We then initiated the FlexPepDock 
protocol using each of these eleven peptides in close proximity to the tentative NHE binding 
site at the surface of RACK1. The protocol yielded 200 possible structures of which only the 
Rosetta score value for the most energetically favourable structure was retained and 
presented under Figure 18B. The most energetically favourable structure created yielded a 
result of -18.263 Rosetta energy units; it was a structure formed with Peptide C which spans 
from W-538 to K-547 of the NHE6 sequence. The interface energy score for this peptide was 
significantly lower than other peptides except for peptide B, D and J (peptide B, p=0.0763; 
peptide D, p=0.0901 and peptide J, p=0.0983). The search for key residues of the NHE6 
RACK1 binding domain was further refined by creating four more 10 amino acid peptides 
derived from Peptide C (Figure 18C). The derived peptides were created by sequentially 
removing one amino acid from the C-terminal end and adding another to the N-terminal end. 
Two of these new peptides produced structures that were even more energetically favourable 
than Peptide C (Figure 18D).
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Figure 18. Simulation of peptide-protein interaction through molecular docking 
refinement protocol. 
A) Arbitrary separation of the 62aa [527-588]-NHE6 segment into 11 overlapping 10aa 
peptides identified from A to K. B) Interface energy score of the 11 peptides submitted to 
Flexpepdock molecular docking refinement protocol with the tentative NHE binding pocket 
at the surface of RACK1. Interface energy score is expressed in Rosetta energy units. C) 
Generation of four intermediate peptides to peptides B and C. New peptides were identified 
from C-1 to C-4. D) I_sc of peptide C and four derivatives submitted to Flexpepdock 
molecular refinement protocol with the possible RACK1 binding site. 
 
These energetically favourable peptides correspond to Peptide C-2 with -21.2428 Rosetta 
energy units and Peptide C-4 with -18.8083 Rosetta energy units. The interface energy score 
associated with Peptide C-4 was significantly lower than any other peptide tested through the 
docking protocol.  
 
Following the molecular docking refinement protocol experiment, we inspected the 3D 
generated structures with the lowest interface energy score for each simulation presented in 
Figure 18D to identify which residues could act as anchorage residues at the predicted NHE 
binding pocket of RACK1. Shown in Figure 19 is the putative RACK1 binding pocket and 
flexamples of interaction interfaces for the three peptides previously predicted to form the 
most energetically favourable interactions with RACK1; residues partially or completely 
buried in or around the predicted NHE binding pocket of RACK1 are shown in red. The 
buried residues were identified for each of the 20 structures examined (4 structure for each 
of the 5 peptides); the distribution of buried residues is shown in percentage in Figure 19A. 
From all structures examined, 5 residues were found to be partially or completely buried in 
at least 50% of cases. These residues in order of prevalence were, Y-539 (95%), F-535 (88%), 
R-536 (75%), W-538 and Y-545 (67%). Since Tyrosine 539 was found to be the most often 
buried in our simulations it is predicted to be central to the NHE6/RACK interaction 
interface. Several of the residues previously marked as possible anchorage residues were 
observed to form favourable interactions with RACK1, in this model, by becoming buried in 
surface cavities. 
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Figure 19. Examination of peptide-protein molecular docking results for buried 
residues. 
A) Frequency in which each residue, from the top structures generated with docking 
simulations, was found to be at least partially buried in the predicted binding pocket identified 
at the surface of RACK1. The residues that were found to be buried in at least 50% of the 
structures examined are shown in red. B) View of the predicted NHE binding pocket of 
RACK1 identified using IsoCleft Finder (violet) at the surface of the bottom face of RACK1 
(green). C) View of peptide C-4 after docking, residues that are partially or completely buried 
are shown in red, other residues are shown in blue. Of the four residues implicated, Y-539 
occupies the innermost cavity. D) View of peptide C-2 after docking. Of the three residues 
implicated, W-538 occupies the innermost cavity.   E) View of peptide C after docking. Of 
the three residues implicated, F-541 occupies the innermost cavity. Images captured with 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
 
4. DISCUSSION 
The current work shows evidence that hypoxia increases RACK1 and NHE6 complex 
formation in both HT1080 and MDA-MB0231 cell lines. We also provide evidence that 
formation of such a complex is reversible and has structural and functional properties of 
transient protein-protein interactions. Since direct protein interaction between RACK1 and 
NHE6 had previously been reported to occur (Ohgaki et al, 2008) and had been shown to 
play a part in regulating cell surface level of NHE6, this finding was the first indication that 
RACK1 may be linked to our previous findings on hypoxia triggered plasma membrane 
NHE6 increase, intra-vesicular compartments acidification, doxorubicin intracellular cluster 
formation and resistance to doxorubicin. To confirm the relationship between RACK1 and 
NHE6 interaction and the list of effects observed in hypoxia above, we constructed a 
mammalian expression vector for expression of a peptide corresponding to the 527-588 
segment of the human NHE6 sequence known to interact with RACK1. The expressed 
NHE6527-588 peptide, in our experimental cell models, was meant to interact with RACK1 and 
thus compete with the native interaction. Functionality of this peptide was first validated by 
an immunoprecipitation experimental design that showed interference with the formation of 
a complex between human NHE6 and RACK1 otherwise triggered by hypoxia (Figure 7). 
Although such competing effect could be appreciated following transient or stable expression 
of the peptide, a seemingly more drastic result with the stably expressed peptide has brought 
us to favour stable expression for the following steps of the experimental design. The use of 
a stable empty vector cell line as experimental control in this initial experiment would have 
however been preferable to ensure beyond doubt that the differences between the transient 
and stable peptide cell lines are not due to cellular alterations following Geneticin selection. 
 
The next phase of our study involved assessment of expressed NHE6527-588 peptide capacity 
to prevent NHE6 translocation to the plasma membrane; an effect previously shown to be 
mediated through a process involving NHE6 and RACK1 interaction. HT1080 or MDA-MB-
231 exposition to 1% O2 hypoxia for 4h induced an increase in plasmalemmal NHE6 
localization for both cells; an effect that was effectively repressed by NHE6527-588 peptide 
expression (Figure 8). Since our working hypothesis postulated that NHE6 translocation to 
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the plasma membrane would contribute to acidification of endosomal/lysosomal 
compartments, leading to weak base therapeutic trapping and ultimately increased resistance 
to those therapeutics; we next proceeded to test the impact of NHE6527-588 peptide expression 
on each of these presumably cascading ramifications. Consistent with the previous result, 
expression of NHE6527-588 peptide in hypoxic cells was indeed found to produce a protective 
effect against endosomal/lysosomal acidification (Figure 9) and what appears to be 
doxorubicin trapping (Figure 10). In a parallel set of experiments (performed by another 
student of the laboratory, Fabrice Lucien) using MTT survival assays conducted with the 
same cell lines, it was shown that resistance to several weak base therapeutics, but not to 
weak acid therapeutics, was reinforced with exposition to hypoxia (Lucien et al, 2017) (result 
not shown). Once again, this effect was diminished through expression of the NHE6527-588 
peptide, giving further support to the hypothesis that the different effects observed under 
hypoxia in this study are interconnected as described above. It should be noted that under 
normoxia, stable expression of the NHE6527-588 peptide in HT1080 cells had no visible effect 
on sensitivity to doxorubicin.  
 
Additionally, preliminary results obtained regarding the correlation of cellular ROS levels 
and the sub-cellular distribution of doxorubicin (Figure 12), taken together with results 
indicating that PKC mimics the effect of hypoxia on NHE6 translocation (Figure 11), allow 
us to propose a model for the series of molecular events that may have led to doxorubicin 
trapping in our study (Figure 20). We propose that hypoxia induces increased mitochondrial 
ROS production which acts as a secondary messenger responsible for the activation of PKC 
isozyme(s) (Cosentino-Gomes et al, 2012). Once in an open active conformation, PKC 
isozymes can bind RACK1 (Adams et al, 2011) which in many cases triggers translocation 
of the protein complex towards the plasma membrane (Bourd-Boittin et al, 2008). It is 
conceivable that the formation of a complex with active PKC acts as a trigger that allows 
formation of the transient RACK1/NHE6 interaction leading to NHE6 translocation to the 
plasma membrane as a PKC/RACK1/NHE6 complex. As RACK1 and NHE6 appear to be 
interacting in a transitory manner, it is unlikely that RACK1 itself acts to anchor NHE6 to 
the plasma membrane for a sustained period of time. It is more likely that RACK1 acts to 
favour anchorage of NHE6 through an adaptor such as FlnA. This possibility is supported by 
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previous findings indicating that RACK1 interacts with FlnA to regulate plasma membrane 
levels of the cystic fibrosis transmembrane conductance regulator (Smith et al, 2013). One 
step of this mechanism was actually validated by the study of Lucien et al (2017) that showed 
through immunoprecipitation that PKC becomes part of a complex with RACK1 and NHE6 
in HT1080 and MDA-MB-231 cells following exposition to hypoxia.  
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Figure 20. Proposed model of cellular events in hypoxia-induced NHE6 translocation 
to the plasma membrane.  
Hypoxia induces increased mitochondrial ROS production that activates PKC. Once in an 
open active conformation, PKC binds RACK1 which triggers interaction with NHE6 and 
translocation of the protein complex towards the plasma membrane. RACK1 then acts to 
regulate cell surface levels of NHE6 by allowing the formation of a complex with an 
unknown adaptor protein. Reduced NHE6 levels in the endosomes results in lower pH of 
those compartments and increased doxorubicin ion-trapping.  
 
The series of results illustrated above identify the interaction between NHE6 and RACK1 as 
a promising potential therapeutic target for the eventual development of therapeutics against 
chemoresistance. Although it is true that normalizing endosomal/lysosomal pH may not be 
enough to counter resistance to chemotherapy by itself in a microenvironment where the ECF 
is acidic and weak base therapeutics are partitioned out of the cell, it should be kept in mind 
that vesicular compartments can reach much lower pH values and that although smaller in 
volume, may have a larger potential to sequester weak base therapeutics. Although the 
activity of NHE6 when located at the plasma membrane has not been characterized to date, 
it is possible that similarly to NHE1, NHE6 may further contribute to ECF acidification in 
that location. Despite that fact, there remain several unknown variables that should ideally 
be uncovered before this therapeutic target can be fully exploited. Among other things, the 
specificity of such prospective therapeutic approach needs to be more closely examined. As 
the amino acid sequence from which the NHE6527-588 peptide was derived is highly conserved 
in other intracellular members of the NHE protein subfamily (Figure 14) and human NHE7 
and NHE9 have also been shown to interact with RACK1 (Ohgaki et al, 2008), it is highly 
probable that our competitive peptide also affects RACK1 interaction with these other two 
exchangers. Evolutionary retention of NHE6 and 9, which share a similar subcellular 
localization pattern, suggest that these two transporters must have a distinctive role to play; 
comparative studies are currently lacking to illustrate distinctions that exist between their 
roles. It is a definite possibility that regulation of these transporters expression, activity or 
localization may be impacted differently by the same stimuli. Complementary experiments 
from our laboratory revealed that shRNA depletion of NHE9 does not significantly alter 
endosomal pH and doxorubicin ion-trapping in HT1080 and MDA-MB-231 cells (Lucien et 
al, 2017). It is unclear if NHE9 is also a contributor to ion trapping of weak base therapeutics 
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in other cell models or if on the other hand, it serves to sensitize cancer cells to chemotherapy. 
If NHE9 was found to play a role counter to NHE6 regarding resistance to chemotherapy, 
relative expression of NHE6 and NHE9 in tumor biopsies may have to be considered in order 
to determine the adequate therapeutic approach. We cannot disregard that our competitive 
peptide may additionally prevent interactions with unexpected partners and thus have effects 
other than those for which it was conceived. As is the case for any experimental design, there 
were several limitations associated with this study that could be mitigated in the future. 
Namely, as mentioned throughout, further experimental controls would have occasionally 
been warranted to strengthen our findings. For some experiments, particularly the co-IP 
experiments, we would have wished to be able to further replicate the results in order to 
confirm our findings beyond doubt. We were ultimately unable to do so because of the 
timeliness, technicality and costliness associated with such experiments. Although, the 
confocal microscopy experiments offer much flexibility in experimental designs and permit 
the capture of striking images, they are not very scalable and generally restrain results to a 
relatively small number of cells. Other experiments such as plasma membrane protein 
biotinylation coupled to western blotting could prove more effective alternatives (Caldeira et 
al, 2016). Regardless of these considerations, the mechanism of chemoresistance observed 
in our cellular models is likely to be observed in many clinical cases and to present an 
interesting therapeutic target for many types of cancers.  
 
The second portion of our study first involved detailed examination of the [527-588]-NHE6 
segment in search of key amino acid residues in the NHE6/RACK1 interaction. Multiple 
methods of analysis that included MSA of a NHE intracellular subfamily, calculation of 
residue conservation index, protein disorder propensity predictions and scanning of the 
sequence for other characteristics of transient interactions allowed us to isolate the segment 
contained in [527-588]-NHE6 critical for the RACK1 interaction. The portion of the 
sequence in question is a 28 amino acid segment that stretches from F-536 to P-563 and that 
is particularly well-conserved (Figure 14).  
 
The L-534 to P-563 sequence can be further subdivided into two distinct but interconnected 
segments. First, the proximal segment ranges from L-534 to K-547 and contains as many as 
 
 
84 
six putative anchor residues. A molecular docking simulation indicates that this region is 
indeed the most likely one to form an energetically favourable interaction (Figure 18) with 
the RACK1 binding site identified in figure 17. Of the six potential anchor residues 
previously identified, five were predicted to become buried in the RACK1 interface in at 
least 50% of the complex structures generated through a molecular docking protocol (Figure 
19). Of these five residues, Y-539 was most often predicted to become buried in the complex 
structure (95%, Figure 19A). This finding is particularly interesting as phosphorylation of 
the cytoplasmic tail of members of the NHE protein family is one of the mechanisms that has 
been identified to modulate the activity and localization of these ion channels (Baumgartner 
et al, 2004). Next, the distal segment ranges from P-548 to P-563. It is a segment that is 
highly enriched in neutral polar residues (Figure 15), that contains four proline residues and 
that was predicted to be ID (Figure 16).  Whereas the proximal segment of the F-536 to P-
563 sequence might bind the cavity identified with Isocleft Finder through anchor residues, 
the distal segment might interact with the “aromatic cradle” identified in figure 17 as is 
typical for transient interactions. This proposed two step interaction would be logical as the 
structure of the proximal segment would allow for the initial point of contact to form the 
protein interface and the distal segment would then strengthen the interaction by wrapping 
itself around the “aromatic cradle”. This proposed mechanism would be in line with the 
disorder-to-order transition that is often observed in the formation of a transient interaction 
between proteins (Janin et al, 2008). In this context, one can propose as a therapeutic strategy, 
the design of a peptide mimetic (London et al, 2008) containing the anchor residues, 
identified here in the proximal segment, as such a drug should prevent the initial step in the 
formation of the interaction interface between RACK1 and NHE6. This peptidomimetic 
would have to encompass some or all of the L-534 to K-547 sequence. A peptide formed of 
this fourteen amino acid sequence would be estimated to have a mass of 1.95 kDa1.  
 
Many intracellular protein-protein interactions were considered to be undruggable until the 
mid 2000’s, but there have since been many advancements made in chemical modifications 
to peptide therapeutics that now make these realistic targets (Tsomaia, 2015). New peptide 
                                                 
1Genscript’s peptide molecular weight calculator accessed at: 
https://www.genscript.com/account/customerpeptide.html 
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modifications have served to reduce proteolytic degradation, improve peptide conformation 
stability and allow greater cell permeability (Cromm et al, 2005). The adequate approach for 
chemical modifications depends on the shape of the interface; the creation of either stapled 
peptides or macrocycle peptides could prove to be effective in targeting the RACK1/NHE6 
interaction interface (Dougherty et al, 2017). The approach of stapled peptides is used to 
stabilize structured epitopes in peptides of up to 60 amino acids (Cromm et al, 2005). Since 
α-helices are abundantly found in protein-protein interactions their stabilization can be 
particularly useful in the design of inhibitors. One prominent example was the design of a 
stapled peptide for the inhibition of the P53-MDM2 interaction mentioned within; this 
peptide which is named ALRN-6924 (Aileron Therapeutics) and is currently undergoing 
phase 1 clinical trial (Dougherty et al, 2017). Macrocycle peptides involve cyclization of a 
linear peptide by joining ends with a heteroaromatic linker (Saito & Bode, 2016). Similarly 
to grafted peptides, macrocycles also stabilize peptide secondary structures and can improve 
passive diffusion across the cell membrane. They are particularly well suited for large and 
relatively flat binding site surface areas where they can display antibody-like binding 
affinities through multiple points of contacts (Dougherty et al, 2017). Macrocyclic peptides 
typically have a molecular mass between 0.5 and 2.0 kDa (Dougherty et al, 2017) which 
places the [534-547]-NHE6 segment in the appropriate size range. 
 
This study provided the foundation on which to establish the design of a potential peptide 
mimetic to be used as a therapy to prevent the occurrence of pH-mediated resistance to 
chemotherapy. Much effort would still be required to evaluate the safety of using such a 
compound as it is currently unknown if the NHE6/RACK1 interaction plays physiological 
roles aside from its roles described in cancer. As an example, it would be important to 
evaluate whether this interaction serves an important role in the brain, where NHE6 is highly 
expressed. NHE1 excessive activation in response to acidosis has been shown to exacerbate 
brain injury in perinatal hypoxia-ischemia (Uria-Avellanal & Robertson, 2014). This 
outcome is believed to result from intracellular Na+ overload leading to ion flow reversal 
through the Na+/Ca2+ exchanger and subsequently cell death. It is currently unknown if 
intracellular Na+/H+ exchangers have a similar effect or on the contrary act to attenuate 
ischemic brain injuries such as in the case of a stroke.  
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In addition to identifying the molecular determinants for future design of a peptide inhibitor, 
this study has made headways describing pathways involved in hypoxia induced 
chemoresistance. Mechanisms proposed here could eventually lead to the identification of 
other therapeutic targets as molecular events behind pH-mediated chemoresistance become 
better understood. 
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